06/04/2020

Date Journal Title Study type Country Authors Link Trial identifier Intervention Main question 19‐Mar‐2021 EBioMedicine Itraconazole for COVID‐19: preclinical open‐label, Belgium Liesenborghs L et https://www.ncbi.nlm.ni EudraCT 2020‐ Itraconazole To investigate if itraconazole is studies and a proof‐of‐concept randomized, al h.gov/pmc/articles/PMC 001243‐15 (antifungal) effective for the treatment randomized clinical trial single‐ 7979145/pdf/main.pdf and/or prevention of COVID‐ center pilot 19. trial

11‐Mar‐21 Nature Sensitivity of SARS‐CoV‐2 B.1.1.7 to vaccine International Collier A.C. et al https://www.nature.com/Cambridge Central BNT162 ‐ vaccine Assessement of immune mRNA vaccineelicited antibodies Research Ethics responses following Committee vaccinaon with mRNA based (17/EE/0025). vaccine BNT162

11‐Mar‐21 JAMA Immunogenicity of the Ad26.COV2.S RCT vaccine ‐ International Stepherson K., et al https://jamanetwork.com NCT04436276 Ad26.COV2.S vaccine (J Evaluation of the Vaccine for COVID‐19 immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS‐CoV‐2 spike‐specific humoral and cellular immune responses

24‐Mar‐21 The Lancet Safety and immunogenicity of a RCT ‐ vaccine China ShilongYang, et al. https://www.sciencedirec NCT04445194 and ZF2001 Vaccine ‐ To assess the safety and Infectious recombinant tandem‐repeat dimeric protein subunit immunogenicity of this Diseases RBD‐based protein subunit vaccine vaccine against COVID‐ vaccine, ZF2001, and (ZF2001) against COVID‐19 in adults: two 19 using a dimeric determine the appropriate randomised, double‐blind, placebo‐ form of the receptor‐ dose and schedule for an controlled, phase 1 and 2 trials binding domain (RBD) efficacy study. of the SARS‐CoV‐2 spike protein as the antigen

25‐Mar‐21 Therapeutic AdClinical effectiveness of drugs in meta‐analysisMexico Zuñiga RAA, et al. https://journals.sagepub.cNA remdesivir, chloroquineTo assess the clinical hospitalized patients with COVID‐19: a effectiveness of drugs used in systematic review and meta‐analysis hospitalized patients with COVID‐19 infection. 25‐Mar‐21 JAMA Effect of Helmet Noninvasive Ventilation RCT International Domenico Luca Griec https://jamanetwork.com NCT04502576 oxygen To assess whether helmet vs High‐Flow Nasal Oxygen on Days Free noninvasive ventilation can of Respiratory Support in Patients With increase the days free of COVID‐19 and Moderate to Severe respiratory support in patients Hypoxemic Respiratory Failure The with COVID‐19 compared with HENIVOT Randomized Clinical Trial high‐flow nasal oxygen alone.

18‐Mar‐21 JAMA Effect of Intermediate‐Dose vs Standard‐ RCT Iran INSPIRATION Investighttps://jamanetwork.com NCT04486508 enoxaparin, 1 mg/kg daTo evaluate the effects of Dose Prophylactic Anticoagulation on intermediate‐dose vs standard‐ Thrombotic Events, Extracorporeal dose prophylactic Membrane Oxygenation Treatment, or anticoagulation among Mortality Among Patients With COVID‐ patients with COVID‐19 19 Admitted to the Intensive Care Unit admitted to the intensive care The INSPIRATION Randomized Clinical unit (ICU) Trial

Effect of a genetically engineered interferon‐alpha versus traditional https://www.tandfonline Does genetically engineered Infectious ChiCTR200002963 Genetically 23‐Feb‐21 interferon‐alpha in the treatment of RCT China Li et al. .com/doi/full/10.1080/0 IFN have a better clinical effect Diseases 8 engineered IFN‐alpha moderate‐to‐severe COVID‐19: a 7853890.2021.1890329 than the traditional? randomised clinical trial NCT04324606 Single‐dose administration and the https://www.sciencedire (COV001), influence of the timing of the booster Pooled Do 3‐month dose vaccination Oxford COVID ct.com/science/article/pi NCT04400838 19‐Feb‐21 The Lancet dose on immunogenicity and efficacy of analysis of 4 UK ChAdOx1 vaccine have advantages over a short Vaccine Trial Group i/S0140673621004323?v (COV002), and ChAdOx1 nCoV‐19 (AZD1222) vaccine: a RCT dose programme? ia%3Dihub NCT04444674 pooled analysis of four randomised trials. (COV005) Efficacy of ChAdOx1 nCoV‐19 (AZD1222) https://www.thelancet.c vaccine against SARS‐CoV‐2 variant of Exploratory NCT04400838, Is ChAdOx1 vaccine effective om/journals/lancet/articl 30‐Mar‐21 The Lancet concern 202012/01 (B.1.1.7): an analysis of UK Emary et al. and ISRCTN ChAdOx1 vaccine against SARS‐CoV variant e/PIIS0140‐ exploratory analysis of a randomised RCT 15281137 B.1.1.7 ? 6736(21)00628‐0/fulltext controlled trial Mavrilimumab in patients with severe COVID‐19 pneumonia and systemic https://www.thelancet.c NCT04399980, N Would mavrilimumab improve The Lancet hyperinflammation (MASH‐COVID): an om/journals/lanrhe/artic CT04463004, 17‐Mar‐21 RCT USA Cremer et al. Mavrilimumab outcomes in patients with Rheumatology investigator initiated, multicentre, le/PIIS2665‐ and NCT044925 COVID‐19? double‐blind, randomised, placebo‐ 9913(21)00070‐9/fulltext 14. controlled trial 8‐Mar‐2021 Lancet Infect Safety and immunogenicity of an Vaccine trial India Ella R., et al. https://www.thelancet.c NCT04471519 BBV152 (Bharat To evaluate the safety and Dis inactivated SARS‐CoV‐2 vaccine, BBV152: Phase II om/journals/laninf/articl Biotech) vaccine immunogenicity of an interim results from a double blind, e/PIIS1473‐ inactivated SARS‐CoV‐2 randomised, multicentre, phase 2 trial, 3099(21)00070‐0/fulltext vaccine, BBV152. and 3‐month follow‐up of a double‐blind, randomised phase 1 trial

4‐Mar‐2021 JAMA Effect of Ivermectin on Time to RCT Phase III Colombia/US Lopez‐Medina E., https://jamanetwork.co NCT04405843 Ivermectin To determine whether Resolution of Symptoms Among Adults A et al. m/journals/jama/fullartic ivermectin is an efficacious With Mild COVID‐19A Randomized le/2777389 treatment for mild COVID‐19. Clinical Trial 4‐Mar‐2021 Lancet Respir Sarilumab in patients admitted to RCT Phase III International Lescure FX., et al. https://www.thelancet.c NCT04327388 Sarilumab To assess safety and efficacy of Med hospital with severe or critical om/journals/lanres/articl sarilumab, an interleukin‐6 COVID 19: a randomised, double blind, e/PIIS2213‐ receptor inhibitor, in patients placebo‐controlled, phase 3 trial 2600(21)00099‐0/fulltext with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID‐ 19.

4‐Mar‐2021 Lancet Azithromycin for community treatment RCT Phase III UK PRINCIPLE Trial https://www.thelancet.c ISRCTN86534580 Azithromycin To assess the effectiveness of of suspected COVID‐19 in people at Collaborative om/journals/lancet/articl azithromycin to treat increased risk of an adverse clinical Group e/PIIS0140‐ suspected COVID‐19 among course in the UK (PRINCIPLE): a 6736(21)00461‐X/fulltext people in the community who randomised, controlled, open‐label, had an increased risk of adaptive platform trial complications.

1‐Mar‐2021 Antimicrob Human Safety, Tolerability, and RCT Phase I USA Painter W. P., et al. https://aac.asm.org/cont NCT04392219 Molnupiravir, EIDD‐ Single and multiple doses of Agents Pharmacokinetics of Molnupiravir, a ent/early/2021/02/24/A 2801/MK‐4482, molnupiravir were evaluated in Chemother Novel Broad‐Spectrum Oral Antiviral AC.02428‐20 prodrug of the active this first‐in‐human, phase 1, Agent with Acvity Against SARS‐CoV 2 antiviral randomized, double‐blind, ribonucleoside analog placebocontrolled study in 14ß‐d‐N4‐ healthy volunteers, which hydroxycytidine (NHC; included evaluation of the EIDD‐1931) effect of food on pharmacokinetics.

11‐Mar‐2021 JAMA Immunogenicity of the Ad26.COV2.S Vaccine trial USA Kathryn E. Immunogenicity of the NCT04436276 Ad26.COV2.S Vaccine To evaluate the Vaccine for COVID‐19 Phase I Stephenson Ad26.COV2.S Vaccine for (Janssen) immunogenicity of the COVID‐19 | Vaccination | Ad26.COV2.S vaccine JAMA | JAMA Network (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS‐CoV‐2 spike‐specific humoral and cellular immune responses.

10‐Feb‐2021 Signal Effect of human umbilical cord‐derived https://pubmed.ncbi.nlm NCT04288102 Human umbilical cord‐ To assess the efficacy and Transduct mesenchymal stem cells on lung damage .nih.gov/33568628/ derived mesenchymal safety of human umbilical cord‐ Target Ther in severe COVID‐19 patients: a stem cells mesenchymal stem cells (UC‐ Vaccine trial randomized, double‐blind, placebo‐ China Shi et el. MSCs) to treat severe COVID‐ Phase I/II controlled phase 2 trial 19 patients with lung damage, based on our phase 1 data.

9‐Feb‐2021 Vaccine A preliminary report of a randomized RCT phase II US LaurenceChu A preliminary report of a NCT04405076 mRNA‐1273 vaccine To evaluate the safety and controlled phase 2 trial of the safety and randomized controlled immunogenicity of vaccine immunogenicity of mRNA‐1273 SARS‐ phase 2 trial of the safety candidate mRNA‐1273, CoV‐2 vaccine and immunogenicity of encoding the prefusion‐ mRNA‐1273 SARS‐CoV‐2 stabilized spike protein of SARS‐ vaccine ‐ ScienceDirect CoV‐2.

03‐Mar‐21 Plos Med Early versus deferred anti‐SARS‐CoV‐2 RCT Chile Balcells MA et al https://www.ncbi.nlm.ni NCT04375098 Convalescent Plasma To evaluate the efficacy and convalescent plasma in patients h.gov/pmc/articles/PMC safety of early Convalescent admitted for COVID‐19: A randomized 7929568/pdf/pmed.100 Plasma therapy in COVID-19 progression phase II clinical trial 3415.pdf 07‐Mar‐21 Thrombosis Sulodexide in the treatment of patients RCT Mexico Gonzalez Ochoa AJ https://pubmed.ncbi.nlm ISRCTN59048638 Oral dose of To evaluate the effect of and with early stages of COVID‐19: a et al .nih.gov/33677827/ sulodexide (500 LRU sulodexide when used in the Haemostasis randomized controlled trial twice a day) or early clinical stages of COVID‐ placebo for 21 days 19 16‐Mar‐21 NEJM Efficacy of the ChAdOx1 nCoV‐19 Covid‐ RCT South Africa Madhi SA et al https://www.nejm.org/d NCT04444674 ChAdOx1 nCoV‐19 To assess the safety and 19 oi/pdf/10.1056/NEJMoa vaccine (AZD1222) efficacy of the ChAdOx1 nCoV‐ Vaccine against the B.1.351 Variant 2102214?articleTools=tr 19 vaccine (AZD1222) in ue people not infected with the human immunodeficiency virus (HIV) in South Africa.

https://www.nejm.org/d Evaluation of the effectiveness of BNT162b2 mRNA Covid‐19 Vaccine in a BNT162b2 mRNA Covid‐ the BNT162b2 mRNA vaccine 24‐Feb‐21 NEJM Vaccine Israel Dagan N., et al. oi/10.1056/NEJMoa2101 NA Nationwide Mass Vaccination Setting 19 Vaccine based on data from Israel’s largest 765 health care organization.

Exploratory analyses of the impact Single‐dose administration and the influence https://www.thelancet.c on immunogenicity and efficacy of of the timing of the booster dose on extending the interval between om/journals/lancet/articl ChAdOx1 nCoV‐19 19‐Feb‐21 Lancet immunogenicity and efficacy of ChAdOx1 Vaccine UK Voysey M., et al. NA priming and booster doses. e/PIIS0140‐ vaccine nCoV19 (AZD1222) vaccine: a pooled analysis ‐ Immunogenicity and protection of four randomised trials 6736(21)00432‐3/fulltext afforded by the first dose, before a booster dose has been offered.

https://www.thelancet.c To examine early reductions in Early rate reductions of SARS‐CoV‐2 infection om/journals/lancet/articl SARS‐CoV‐2 infection and 18‐Feb‐21 Lancet and COVID‐19 in BNT162b2 vaccine Vaccine Israel Amit S., et al. NA BNT162b2 vaccine e/PIIS0140‐ COVID19 rates in vaccinated recipients 6736(21)00448‐7/fulltext HCWs. Association of Convalescent Plasma https://jamanetwork.co Is treatment with convalescent Treatment With Clinical Outcomes in 28‐Feb‐21 JAMA Metaanalysis International Janiaud et al. m/journals/jama/fullartic NA convalescent plasma plasma associated with improved Patients With COVID‐19 A Systematic Review clinical outcomes? and Meta‐analysis le/2777060

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Effect of a Single High Dose of Vitamin D3 on Patients With Moderate To investigate the effect of a Hospital Length of Stay in Patients With single high dose of vitamin D3 on 17‐Feb‐21 JAMA RCT Brazil Murai et al. to Severe COVID‐19: A NCT04449718 Vitamin D3 Moderate to Severe COVID‐19. A hospital length of stay in patients Randomized Clinical Trial Randomized Clinical Trial with COVID‐19. | Complementary and Alternative Medicine | JAMA | JAMA Network To examine whether high‐dose zinc and/or high‐dose ascorbic Effect of High‐Dose Zinc and Ascorbic Acid acid reduce the severity or Supplementation vs Usual Care on Symptom Zinc gluconate (50 mg), duration of symptoms compared Length and Reduction Among Ambulatory https://jamanetwork.co ascorbic acid (8000 mg), with usual care among Patients With SARS‐CoV‐2 Infection m/journals/jamanetwork both agents, or standard ambulatory patients with SARS‐ 12‐Feb‐21 JAMA The COVID A to Z Randomized Clinical Trial RCT US Thomas et al. open/fullarticle/2776305 NCT04342728 of care. CoV‐2 infection.

Whether nasopharyngeal Povidone Iodine Mouthwash, Gargle, and https://jamanetwork.co application of PI could reduce the Nasal Spray to Reduce Nasopharyngeal Viral m/journals/jamaotolaryn viral load of patients with Load in Patients With COVID‐19. A gology/fullarticle/277598 Povidone iodine (PI) nonsevere coronavirus disease 4‐Feb‐21 JAMA Randomized Clinical Trial RCT France Guenezan 4 NCT04371965 solutions. 2019 (COVID‐19) symptoms. Early Use of Corticosteroid May Prolong SARS‐ Efficacy and safety of CoV‐2 Shedding in Non‐Intensive Care Unit https://pubmed.ncbi.nlm.ni corticosteroid given to the 22‐Jan‐21 Respiration Patients with COVID‐19 Pneumonia: A RCT China Tang et al. NCT04273321 methylprednisolone h.gov/33486496/ hospitalized patients with COVID‐ Multicenter, Single‐Blind, Randomized 19 Control Trial https://erj.ersjournals.com/ European Efficacy and safety of Early use of nitazoxanide in mild Covid‐19 content/erj/early/2021/01/ Jan‐21 Respiratory RCT Brazil Rocco et al. NCT04552483 nitazoxanide nitrazoxanide in COVID‐19 disease: randomised, placebo‐controlled trial 04/13993003.03725‐ Journal patients 2020.full.pdf Umbilical cord mesenchymal stem cells for https://stemcellsjournals.o Stem Cell COVID‐19 acuterespiratory distress nlinelibrary.wiley.com/doi/ Safety of MSC in COVID‐19 Jan‐21 Transplantation RCT USA Lanzoni et al. NCT04355728 mesenchymal stem cell syndrome: A double‐blind, phase epdf/10.1002/sctm.20‐ patients Medicine 1/2a,randomized controlled trial 0472 https://www.medrxiv.org/c Evaluation of a SARS‐CoV‐2 Vaccine NVX‐ Evaluation of a SARS‐CoV‐2 1‐Mar‐21 MedRxiv RCT USA Neil Formica et al ontent/10.1101/2021.02.2 NCT04368988 NVX‐CoV2373 vaccine CoV2373 in Younger and Older Adults Vaccine NVX‐CoV2373 6.21252482v1.full.pdf https://www.ncbi.nlm.nih.g Archives of Efficacy of favipiravir in COVID‐19 treatment: ov/pmc/articles/PMC78296 chloroquine and To evaluate the efficacy of 25‐Jan‐21 RCT Egypt Dabbous HM et al NCT04351295 Virology a multi‐center randomized study 45/pdf/705_2021_Article_4 favipiravir favipiravir 956.pdf https://www.nejm.org/doi/ NCT04381936; To evaluate the effects of Dexamethasone in Hospitalized Patients with Horby P et al 25‐Feb‐21 NEJM RCT UK pdf/10.1056/NEJMoa20214 ISRCTN number, dexamethasone potential treatments in patients Covid‐19 (RECOVERY Group) 36?articleTools=true 50189673 hospitalized with Covid‐19 at To assess the efficacy and safety https://www.nejm.org/doi/ Tocilizumab in Hospitalized Patients with of tocilizumab in hospitalized 25‐Feb‐21 NEJM RCT USA Rosas IO et al pdf/10.1056/NEJMoa20287 NCT04320615 tocilizumab Severe Covid‐19 Pneumonia patients with severe Covid‐19 00?articleTools=true pneumonia REMAP‐CAP To assess the efficacy of https://www.nejm.org/doi/ Interleukin‐6 Receptor Antagonists in ClinicalTrials.gov tocilizumab and interleukin‐6 receptor antagonists 25‐Feb‐21 NEJM RCT UK Gordon AC et al pdf/10.1056/NEJMoa21004 Critically Ill Patients with Covid‐19 number, sarilumab in critically ill patients with Covid‐ 33?articleTools=true NCT02735707 19 Effect of tocilizumab on clinical outcomes at Does tocilizumab improves clinical 15 days in patients with severe or critical https://www.bmj.com/c 20‐Jan‐21 BMJ RCT Brazil Veiga, V.C. et al. NCT04403685 tocilizumab outcomes for patients with severe coronavirus disease 2019: randomised ontent/372/bmj.n84 or COVID‐19?. controlled tria Interim Results of a Interim Results of a Phase 1–2a Trial of vaccine Phase Phase 1–2a Trial of NCT04436276. The safety and immunogenicity 13‐Jan‐21 NEJM USA Sadoff J., et al. Ad26.COV2.S vaccine Ad26.COV2.S Covid‐19 Vaccine I/IIa Ad26.COV2.S Covid‐19 opens in new tab. profiles of Ad26.COV2 Vaccine | NEJM

To assess whether convalescent https://www.medrxiv.or plasma with high antibody levels expanded rather than low antibody levels is Early Safety Indicators of COVID‐19 g/content/10.1101/2020 13‐Jan‐21 NEJM access USA Joyner et al. NCT04338360 Convalescent plasma associated with a lower risk of Convalescent Plasma in 5,000 Patients .05.12.20099879v1.full.p program death. df Primary outcome: death within 30 days after plasma transfusion.

Short term, high‐dose vitamin D https://pmj.bmj.com/co Do high doses of cholecalciferol Postgraduate supplementation for COVID‐19 disease: a ntent/early/2020/11/12/ 11‐Nov‐20 RCT India Rastogi et al. NCT04459247 Vitamin D lead to SARS‐CoV‐2 negativity in Medical Journal randomised, placebo‐controlled, study postgradmedj‐2020‐ greater proportions? (SHADE study) 139065 Safety and immunogenicity of S‐Trimer (SCB‐ https://www.thelancet.c 2019), a protein subunit vaccine candidate Phase I om/journals/lancet/articl Dose‐finding and adjuvant 29‐Jan‐21 The Lancet for COVID‐19 in healthy adults: a phase 1, Multinational Richmond et al. NCT04405908 S‐Trimer (SCB‐2019) vaccine trial e/PIIS0140‐ justification of SCB‐2019 vaccine randomised, double‐blind, placebo‐ controlled trial 6736(21)00241‐5/fulltext

Safety and efficacy of an rAd26 and rAd5 https://www.thelancet.c vector‐based heterologous prime‐boost Phase III om/journals/lancet/articl Gam‐COVID‐Vac (Sputnik Efficacy and safety of Gam‐COVID‐ 02‐Feb‐21 The Lancet Russia Logunov et al. NCT04530396 COVID‐19 vaccine: an interim analysis of a vaccine trial e/PIIS0140‐ V) Vac randomised controlled phase 3 trial in Russia 6736(21)00234‐8/fulltext

Early High‐Titer Plasma Early High‐Titer Plasma Does convalescent plasma reduce Therapy to Prevent 06‐Jan‐21 NEJM Therapy to Prevent Severe RCT Argentina Libster R, et al. NCT04479163 Convalescent plasma the development of severe Severe Covid‐19 in Older Covid‐19 in Older Adults respiratory disease? Adults | NEJM

https://www.nejm.org/d Efficacy, Safety, and Efficacy and Safety of the mRNA‐1273 SARS‐ Vaccine ‐ oi/full/10.1056/NEJMoa2 mRNA‐1273 SARS‐CoV‐2 Immunogenicity of mRNA‐1273 30‐Dec‐21 NEJM USA Baden LR, et al. NCT04470427 CoV‐2 Vaccine phase III 035389?query=featured Vaccine Vaccine in Adults Aged 18 Years _coronavirus and Older to Prevent COVID‐19 Enisamium is an inhibitor of the SARS‐CoV‐2 https://www.medrxiv.or RNA polymerase and shows improvement of g/content/10.1101/2021 Efficacy and safety of enisamium 12‐Jan‐21 MedRxiv RCT Multinational Holubovska et al. NCT04682873 enisamium recovery in COVID‐19 patients in an interim .01.05.21249237v1.full‐ at COVID‐19 patients analysis of a clinical trial text

Safety and immunogenicity of SARS‐CoV‐2 https://www.medrxiv.or recombinant protein vaccine formulations in Vaccine trial Safety and imunogenicity of CoV2 20‐Jan‐21 MedRxiv Multinational Goepfert et al. g/content/10.1101/2021 NCT04537208 CoV2 preS dTM vaccine healthy adults: a randomised, placebo‐ phase I/II preS dTM vaccine controlled, dose‐ranging study .01.19.20248611v1 https://link.springer.com Annals of Pilot trial of high‐dose vitamin C in critically ill 09‐Jan‐21 RCT China Zhang et al. /article/10.1186/s13613‐ NCT04264533 Vitamin C Effect of high doses of vitamin C Intensive Care COVID‐19 patients 020‐00792‐3 Efficacy and safety of favipiravir, an oral RNA‐ International https://www.sciencedire dependent RNA polymerase inhibitor, in mild‐ Efficacy and safety of favipiravir in Journal of ct.com/science/article/pi CTRI/2020/05/0251 01‐Feb‐21 to‐moderate COVID‐19: A randomized, RCT India Udwadia et al. favipiravir adults with mild‐to‐moderate Infectious i/S120197122032453X?v 14 comparative, open‐label, multicenter, phase COVID‐19 Diseases 3 clinical trial ia%3Dihub Safety and efficacy of the ChAdOx1 nCoV‐19 https://www.thelancet.c ISRCTN89951424, vaccine (AZD1222) against SARS‐CoV‐2: an phase I/II/III om/journals/lancet/articl NCT04324606, ChAdOx1 nCoV‐19 To test the safety and efficacy of 08‐Dec‐20 Lancet interim analysis of four randomised Multinational Voysey et al. vaccine trial e/PIIS0140‐ NCT04400838, and vaccine the ChAdOx1 nCoV‐19 vaccine controlled trials in Brazil, South Africa, and NCT04444674 the UK 6736(20)32661‐1/fulltext Effect of Baricitinib plus baricitinib (≤14 days) plus Baricitinib plus Remdesivir for Hospitalized Remdesivir for Baricitinib plus remdesivir (≤10 days) vs. 11‐Dec‐20 NEJM RCT USA Kalil A.C., et al NCT04401579 Adults with Covid‐19 Hospitalized Adults with Remdesivir remdesivir alone Covid‐19 | NEJM in hospitalized adults with Covid‐ 19 https://www.nejm.org/d To test the safety and efficacy of Tocilizumab in Patients Hospitalized with 17‐Dec‐20 NEJM RCT USA Salama et al. oi/10.1056/NEJMoa2030 NCT04372186 tocilizumab tocilizumab in hospitalized Covid‐19 Pneumonia 340 patients with Covid‐19 pneumonia https://assets.researchsq Exogenous Surfactant Versus Placebo in the uare.com/files/rs‐ IRCT2009120100280 Is surfactant effective in COVID‐19 31‐Dec‐20 Preprint Treatment of Moderate and Severe ARDS in RCT Iran Ghahremani et al. 136365/v1/adcad24b‐ surfactant 4N12 paients? COVID19: The Pilot Study of a Clinical Trial f7ed‐477b‐a235‐ 235f84f8ce1b.pdf WHO mortality trial of four Repurposed Antiviral remdesivir, repurposed antiviral drugs — Repurposed Antiviral Drugs for Covid‐19 — WHO Soidarity Trial Drugs for Covid‐19 — hydroxychloroquine remdesivir, hydroxychloroquine 02‐Dec‐20 NEJM RCT Multinational NCT04315948 Interim WHO Solidarity Trial Results Consortium Interim WHO Solidarity (HCQ), lopinavir, and (HCQ), lopinavir, and interferon Trial Results | NEJM interferon beta‐1a (IFN) beta‐1a (IFN)— in patients hospitalized with Covid‐19. mRNA 1273 vaccine Durability of Responses immunogenicity 3 months after Durability of Responses Phase I 03‐Dec‐20 NEJM USA Widge A.T., et al. after SARS‐CoV‐2 mRNA‐ NCT04283461 mRNA 1273 vaccine second after SARS‐CoV‐2 mRNA1273 Vaccination vaccine trial 1273 Vaccination | NEJM vaccination

Safety and immunogenicity of INO‐4800 DNA https://www.sciencedire EClinicalMedici Phase I Safety and immunogenicity of INO‐ 24‐Dec‐20 vaccine against SARS‐CoV‐2: A preliminary USA/UK Tebas et al. ct.com/science/article/pi NCT04336410 INO‐4800 DNA vaccine ne vaccine trial 4800 vaccine report of an open‐label, Phase 1 clinical trial i/S2589537020304338

Phase 1/2 trial of SARSCoV‐2 vaccine https://www.nature.com Safety and exploratory humoral Phase I/II ChAdOx1 nCoV‐19 17‐Dec‐20 Nature Med. ChAdOx1 nCoV‐19 with a booster dose UK Barrett J.R., et al. /articles/s41591‐020‐ NCT04400838 and cellular immunogenicity of vaccine trial vaccine AZD1222 induces multifunctional antibody responses 01179‐4 the AZD1222 vaccine Interim study results: effects of REGN‐COV2, a high viral loads with complications REGN‐COV2, a Neutralizing Neutralizing Antibody REGN‐COV2 antibody and death from coronavirus 17‐Dec‐20 NEJM Antibody Cocktail, in RCT USA Weinreich D.M NCT04425629 Cocktail, in Outpatients cocktail disease 2019 (Covid‐19)‐REGN‐ Outpatients with Covid‐19 with Covid‐19 | NEJM COV2 effects on outpatients Safety and immunogenicity clinical trial of an inactivated SARS‐CoV‐2 vaccine, BBV152 (a https://www.medrxiv.or To test the immunogenicity and phase 2, double‐blind, randomised Phase I/II inactivated SARS‐CoV‐2 22‐Dec‐20 preprint ‐ BMJ India Raches et al. g/content/10.1101/2020 NCT04471519 safety of BBV152: 3 µg and 6 µg controlled trial) and the persistence of vaccine trial vaccine, BBV152 with Algel‐IMDG. immune responses from a phase 1 follow‐up .12.21.20248643v1 report A Neutralizing To test the effect of this antibody A Neutralizing Monoclonal Antibody for ACTIV‐3/TICO LY‐ Monoclonal Antibody for 22‐Dec‐20 NEJM RCT Denmark NCT04501978 LY‐CoV555 in patients who are hospitalized Hospitalized Patients with Covid‐19 CoV555 Study Group Hospitalized Patients with Covid‐19. with Covid‐19 | NEJM

To test the effect of Tocilizumab Efficacy of Tocilizumab in Efficacy of Tocilizumab in on multi‐organ dysfunction in a 10‐Dec‐20 NEJM Patients Hospitalized with RCT USA Stone J.H., et al Patients Hospitalized NCT04356937 tocilizumab phase 3 randomized controlled Covid‐19 with Covid‐19 | NEJM trial among hospitalized patients with COVID‐19 infection. https://bmcinfectdis.bio Effect of Arbidol (Umifenovir) on COVID‐19: a medcentral.com/articles/ IRCT2018072504059 To determine the effect of Arbidol 14‐Dec‐20 BMC Infect Dis RCT Iran Marzieh et al. Arbidol (Umifenovir) randomized controlled trial. 10.1186/s12879‐020‐ 6N2 (ARB) on COVID‐19 disease. 05698‐w https://trialsjournal.biom To test the efficacy of Interferon‐β‐ Interferon ß‐1a (IFNß‐1a) in COVID‐19 EudraCT 2020‐ edcentral.com/articles/1 1a (IFNβ‐1a), in COVID‐19 patients 23‐Dec‐20 Trials patients (INTERCOP): study protocol for a RCT Italy Bosi et al. 002458‐25, Interferon ß‐1a (IFNß‐1a) 0.1186/s13063‐020‐ in an open label, randomized randomized controlled trial. NCT04449380 04864‐4 clinical trial. To evaluate the efficacy and safety of BNT162b2 is a lipid Safety and Efficacy of the nanoparticle–formulated, Safety and Efficacy of the BNT162b2 mRNA phase II NCT04368728. nucleoside‐modified RNA vaccine 10‐Dec‐20 NEJM USA Polack F.P., et al. BNT162b2 mRNA Covid‐ BNT162b2 vaccine Covid‐19 Vaccine vaccine trial opens in new tab that encodes a prefusion 19 Vaccine | NEJM stabilized, membraneanchored SARS‐CoV‐2 fulllength spike protein. https://academic.oup.co Journal of Sofosbuvir and daclatasvir for the treatment m/jac/advance‐ IRCT2020040304692 Is sofosbuvir/daclatasvir effective 18‐Dec‐20 Antimicrobial of COVID‐19 outpatients: a double‐blind, RCT Iran Roozbeh et al. article/doi/10.1093/jac/d sofosbuvir, daclatasvir 6N1 in COVID‐19 patiets? Chemotherapy randomized controlled trial kaa501/6041772?login=t rue https://journals.lww.com Intravenous Immunoglobulin Plus /ccejournal/Fulltext/202 To asses the efficacy and safety of 16 November Critical Care Methylprednisolone Mitigate Respiratory RCT USA George Sakoulas, et al. 0/11000/Intravenous_Im NCT04411667 Immunoglobulins IV immunoglobulin in hospitalized 2020 Explorations Morbidity in Coronavirus Disease 2019 munoglobulin_Plus_Met COVID‐19 patients. hylprednisolone.14.aspx To evaluate the effect of Biological Trace Do Zinc Supplements Enhance the Clinical https://link.springer.com combining 23 November Sherief Abd‐Elsalam, Zinc, Element Efficacy of Hydroxychloroquine?: a RCT Egypt /article/10.1007/s12011‐ NCT04447534 chloroquine/hydroxychloroquine 2020 et al. Hydroxychloroquine Research Randomized, Multicenter Trial 020‐02512‐1 and zinc in the treatment of COVID‐19 patients. Effect of Vitamin D3 Supplementation vs https://www.medrxiv.or To determine if vitamin D3 Placebo on Hospital Length of Stay in supplementation can reduce g/content/10.1101/2020 17‐Nov MedRxiv Patients with Severe COVID‐19: A RCT Brazil Murai et al. NCT04449718 Vitamin D3 hospital length of stay in .11.16.20232397v1.full.p Multicenter, Double‐blind, Randomized 3 hospitalized patients with severe Controlled Trial df COVID‐19? To determine whether a single, https://www.medrxiv.or 180 mcg subcutaneous dose of Peginterferon Lambda‐1a for treatment of Peginterferon Lambda‐1a g/content/10.1101/2020 Peginterferon Lambda‐ 23‐Nov MedRxiv outpatients with uncomplicated COVID‐19: a RCT USA Jagannathan et al. NCT04331899 (Lambda) could shorten the .11.18.20234161v1.full.p 1a randomized placebo‐controlled trial duration of viral shedding or df symptoms in patients with mild to moderate COVID‐19. To evaluate the efficacy of https://www.medrxiv.or convalescent plasma with high Prevention of severe COVID‐19 in the elderly g/content/10.1101/2020 titers of SARS‐CoV2 antibody 21‐Nov MedRxiv RCT Argentina Libster et al. NCT04479163 Convalescent plasma by early hightiter plasma .11.20.20234013v1.full.p administered within 72 hours of df mild symptoms to elderly patients with Covid‐19 To estimate the efficacy and A two‐arm, randomized, controlled, multi‐ https://www.medrxiv.or safety of Itolizumab in the centric, open‐label Phase‐2 study to evaluate treatment of cytokine release g/content/10.1101/2020 CTRI/2020/05/0249 02‐Dec MedRxiv the efficacy and safety of Itolizumab in RCT India Kumar et al. Itolizumab syndrome in patients with .12.01.20239574v1.full.p 59 moderate to severe ARDS patients due to moderate to severe acute COVID‐19 df respiratory distress syndrome (ARDS) due to COVID‐19. 5‐Alpha‐Reductase Inhibitors Reduce https://www.medrxiv.or To determine if 5‐alpha‐reductase Remission Time of COVID‐19: Results From a g/content/10.1101/2020 inhibitors (5ARis) are a beneficial 18‐Nov MedRxiv Randomized Double Blind Placebo Controlled RCT Brazil, USA Cadegiani et al. NCT04446429 Dutasteride .11.16.20232512v1.full.p treatment for COVID‐19 if given Interventional Trial in 130 SARSCoV‐2 after SARS‐CoV‐2 infection Positive Men df https://reader.elsevier.c om/reader/sd/pii/S1567 To test the effect Pentoxifylline 576920336766?token=E (PTX) on parameters such as LDH, International Pentoxifylline decreases serum LDH levels lymphocyte count, days of DD4B561C8D7F700793B 11‐Nov Immunopharm and increases lymphocyte count in COVID‐19 RCT Mexico Maldonado et al. COF‐002495 Pentoxifylline hospitalization, mortality, and the 55AFFA9EE8F0CD28010B acology patients: Results from an external pilot study need for intubation on patients E3E0CADC0EF90237E4EF with severe and moderate COVID‐ 73330CF63D0FDA8F33F2 19 F0AD9CA7536BD33F

https://www.nejm.org/d hydroxychloroquine, Repurposed Antiviral Drugs for Covid‐19 — WHO Solidarity Trial ISRCTN83971151, N lopinavir/ritonavir, effects of drugs on in‐hospital 02‐Dec‐20 NEJM RCT Multinational oi/10.1056/NEJMoa2023 Interim WHO Solidarity Trial Results Consortium CT04315948 interferon beta1, mortality 184 remdesivir A Cluster‐Randomized Trial of https://www.nejm.org/d Does postexposure prophylaxis 24‐Nov‐20 NEJM Hydroxychloroquine for Prevention of Covid‐ RCT Spain Mitjà et al. oi/10.1056/NEJMoa2021 NCT04304053 Hydroxychloroquine with hydroxychloroquine prevent 19 801 SARS‐CoV‐2 infection? https://www.nejm.org/d Is treatment with convalescent A Randomized Trial of Convalescent Plasma plasma associated with improved 24‐Nov‐20 NEJM RCT Argentina Simonovich et al. oi/10.1056/NEJMoa2031 NCT04383535 Convalescent plasma in Covid‐19 Severe Pneumonia clinical outcomes in COVID‐19 304 patients? Safety and immunogenicity of ChAdOx1 https://www.sciencedire nCoV‐19 vaccine administered in a prime‐ Safety and immunogenicity of phase II/III ct.com/science/article/pi NCT04400838, 19‐Nov‐20 The Lancet boost regimen in young and old adults UK Ramasamy et al. ChAdOx1 vaccine ChAdOx1 vaccine in young and old vaccine trial i/S0140673620324661?v ISRCTN 15281137 (COV002): a single‐blind, randomised, adults controlled, phase 2/3 trial ia%3Dihub Safety, tolerability, and immunogenicity of https://www.sciencedire an inactivated SARS‐CoV‐2 vaccine in healthy Safety, tolerability and Lancet Infect. I/II vaccine ct.com/science/article/pi 18‐Nov‐20 adults aged 18–59 years: a randomised, China Zhang et al. NCT04352608 CoronaVac vaccine immunogenicity of CoronaVac Dis. trial i/S1473309920308434?v double‐blind, placebo‐controlled, phase 1/2 vaccine clinical trial. ia%3Dihub https://www.medrxiv.or Randomized controlled trial of convalescent Pilot study designed to inform the Bahrain, g/content/10.1101/2020 04‐Nov MedRxiv plasma therapy against standard therapy in 2 RCT Al Qahtani et al. NCT04356534 Convalescent plasma design of a definitive phase 3 Ireland .11.02.20224303v1.full.p patients with severe COVID‐19 disease clinical trial. df https://www.medrxiv.or To evaluate a single Peginterferon‐lambda for the treatment of g/content/10.1101/2020 subcutaneous injection of 12/11/2020 MedRxiv RCT Canada Feld et al. NCT04354259 Peginterferon COVID‐19 in outpatients .11.09.20228098v1.full.p peginterferon‐lambda in df outpatients with COVID‐19. https://reader.elsevier.c om/reader/sd/pii/S1567 Evaluating the effects of Intravenous 576920336729?token=1 To investigate the potential International Immunoglobulin (IVIg) on the management 3C23CAB7F2F51222936F IRCT2015122702572 Intravenous usefulness of IVIg for the 13‐Nov Immunopharm RCT Iran Tabarsi et al. of severe COVID‐19 cases: A randomized 6967643ECEC50F680C6C 6N20 Immunoglobulin management of severe cases of acology controlled trial 1B600298B1211225F0DF Covid‐19. EC4733E630469CDAF7A 7C229585B41FD1EE

To evaluate the therapeutic Randomized Controlled Open Label Trial on International https://www.sciencedire effectiveness of favipiravir the Use of Favipiravir Combined with Inhaled 9 November 2020 Journal of ct.com/science/article/pi Favipiravir, interferon combined with inhaled interferon Interferon beta‐1b in Hospitalized Patients RCT Oman Faryal Khamis, et al. NA (preprint) Infectious i/S1201971220323195?v beta‐1b beta‐1b in adult patients with Moderate to Severe COVID‐19 Diseases hospitalized with moderate to Pneumonia ia%3Dihub severe COVID‐19 pneumonia. https://academic.oup.co Clinical Randomized, double‐blinded and placebo‐ Assess the safety and Phase 2 m/cid/advance‐ Preprint Infectious controlled phase II trial of an inactivated China Yanchun Che, et al. NCT04412538 Inactivated vaccine immunogenitcity of this vaccine trial article/doi/10.1093/cid/c Diseases SARS‐CoV‐2 vaccine in healthy adults inactiviated vaccine iaa1703/5962856 To evaluate the efficacy of PEP International Post‐exposure prophylaxis with https://www.sciencedire with HCQ for the prevention of 6 November 2020 Journal of hydroxychloroquine for the prevention of Deba Prasad Dhibar, ct.com/science/article/pi RCT India NCT04408456 Hydroxychloroquine COVID‐19 in asymptomatic non‐ (in press) Antimicrobial COVID‐19, a myth or a reality? The PEP‐CQ et al. i/S0924857920304350?v HCW in‐ dividuals who were at Agents Study ia%3Dihub risk for SARS‐CoV‐2 infection

To assess the safety, tolerability, and immunogenicity of CoVLP at Phase 1 trial of a Candidate Recombinant https://www.medrxiv.or Phase 1 three dose levels unadjuvanted Preprint MedRxiv Virus‐Like Particle Vaccine for Covid‐19 Canada Brian J Ward, et al. g/content/10.1101/2020 NCT04450004 CoVLP vaccine vaccine Trial or adjuvanted with either CpG Disease Produced in Plants .11.04.20226282v1 1018 or AS03 in healthy adults 18 to 55 years of age.

An open‐label, randomized trial of the https://www.sciencedire To evaluate the efficacy and E‐Clinical combination of IFN‐κ plus TFF2 with standard ct.com/science/article/pi safety in patients with moderate 27 October 2020 Medicine RCT China Weihui Fu, et al. ChiCTR2000030262 IFN‐κ plus TFF2 care in the treatment of patients with i/S2589537020302911?v COVID‐19 f the combination of (Lancet) moderate COVID‐19 ia%3Dihub IFN‐κ plus TFF2

Safety and efficacy of inhaled nebulised https://www.thelancet.c The Lancet interferon beta‐1a (SNG001) for treatment of om/journals/lanres/articl 2020‐001023‐14, Efficacy and safety of inhaled 12‐Nov‐20 Respiratory RCT UK Monk et al. INF‐beta 1a SARS‐CoV‐2 infection: a randomised, double‐ e/PIIS2213‐ NCT04385095 nebulised interferon beta‐1a Medicine blind, placebo‐controlled, phase 2 trial 2600(20)30511‐7/fulltext

Determine whether fluvoxamine, Fluvoxamine vs Placebo and Clinical https://jamanetwork.co given during mild COVID‐19 Deterioration in Outpatients With 12‐Nov‐20 JAMA RCT USA Lenze et al. m/journals/jama/article‐ NCT04342663 Fluvoxamine illness, prevents clinical Symptomatic COVID‐19A Randomized deterioration and decreases the Clinical Trial abstract/2773108 severity of disease

Antiviral effect of high‐dose ivermectin in https://papers.ssrn.com/ Does ivermectin reduce the viral Preprint The Lancet adults with COVID‐19: a pilot randomised, RCT Argentina Krolewiecki et al. sol3/papers.cfm?abstract NCT004381884 Ivermectin load? controlled, open label, multicentre trial _id=3714649

Efficacy of Convalescent Plasma Therapy https://www.medrxiv.or To compare the efficacy and compared to Fresh Frozen Plasma in Severely g/content/10.1101/2020 safety of convalescent plasma 27‐Oct MedRxiv RCT India Bajpai et al. NCT04346446 Convalescent plasma ill COVID‐19 Patients: A Pilot Randomized .10.25.20219337v1.full.p with fresh frozen plasma (FFP) in Controlled Trial. df severe COVID‐19 patients https://www.medrxiv.or To evaluate the efficacy and A placebo‐controlled double blind trial of safety of hydroxychloroquine in Dubée et al. for the g/content/10.1101/2020 21‐Oct MedRxiv hydroxychloroquine in mild‐to‐moderate RCT France NCT04325893 Hydroxychloroquine adult patients with mild‐to‐ HYCOVID study group .10.19.20214940v1.full.p COVID‐19 moderate COVID‐19 at risk of df worsening. https://www.medrxiv.or To evaluate whether early nitazoxanide therapy would be Early use of nitazoxanide in mild Covid‐19 g/content/10.1101/2020 23‐Oct MedRxiv RCT Brazil Rocco et al. NCT04552483 Nitazoxanide effective in accelerating symptom disease: randomized, placebo controlled trial .10.21.20217208v1.full.p resolution in patients with mild df COVID‐19. https://www.medrxiv.or To test the combinational therapy Controlled randomized clinical trial on using g/content/10.1101/2020 of Ivermectin and Doxycycline in 27‐Oct MedRxiv Ivermectin with Doxycycline for treating RCT Iraq Hashim et al. NCT04591600 Ivermectin + Doxycycline .10.26.20219345v1.full.p treating COVID‐19 patients at COVID‐19 patients in Baghdad, Iraq df different stages of the disease. Treatment with human umbilical cord‐ https://www.medrxiv.or To assess the efficacy and safety derived mesenchymal stem cells for COVID‐ human umbilical cord‐ of human umbilical cord‐ g/content/10.1101/2020 21‐Oct MedRxiv 19 patients with lung damage: a randomised, RCT China Shi et el. NCT04288102 derived mesenchymal mesenchymal stem cells (UC‐ .10.15.20213553v2.full.p double‐blind, placebo‐controlled phase 2 stem cells MSCs) to treat severe COVID‐19 trial df patients with lung damage.

Umbilical Cord Mesenchymal Stem Cells for https://papers.ssrn.com/ human umbilical cord‐ To determine safety and explore 26‐Oct Lancet pre‐print COVID‐19 ARDS: A Double Blind, Phase 1/2a, RCT USA Lanzoni et al. sol3/papers.cfm?abstract NCT04355728 derived mesenchymal efficacy of Umbilical Cord (UC)‐ Randomized Controlled Trial _id=3696875 stem cells MSC infusions in COVID‐19 ARDS. https://academic.oup.co To determine whether Sofosbuvir/daclatasvir regimens for the sofosbuvir/daclatasvir‐based J Antimicrob m/jac/advance‐ 01‐Nov treatment of COVID‐19: an individual patient Meta‐analysis UK/Iran Simmons et al. N/A sofosbuvir/daclatasvir regimens improve clinical Chemother article/doi/10.1093/jac/d data meta‐analysis outcomes of patients with kaa418/5924537 moderate or severe COVID‐19. https://papers.ssrn.com/ To evaluate the efficacy and Phase 3 Trial of Coronavir (Favipiravir) in 26‐Oct Lancet pre‐print RCT Russia Ruzhentsova et al. sol3/papers.cfm?abstract NCT04501783 Favipiravir safety of favipiravir for treatment Patients with Mild to Moderate COVID‐19 _id=3696907 of mild to moderate COVID‐19 https://www.sciencedire Imunopatholog Treatment of Coronavirus Disease 2019 Efficacy of COVID‐19 convalescent ct.com/science/article/pi 01‐Nov‐20 y and infectious Patients with Convalescent Plasma Reveals a RCT USA Salazar et al. Convalescent plasma plasma transfusion for severe i/S0002944020303709?v diseases Signal of Significantly Decreased Mortality and/or critical COVID‐19. ia%3Dihub https://www.nejm.org/d Efficacy of Tocilizumab in Patients Does tocilizumab prevent 21‐Oct‐20 NEJM RCT USA Stone et al. oi/pdf/10.1056/NEJMoa NCT04356937 Tocilizumab Hospitalized with Covid‐19 intubation or death? 2028836 To determine whether Effect of Tocilizumab vs Usual Care in Adults https://jamanetwork.co tocilizumab (TCZ) improves JAMA Internal Hospitalized With COVID‐19 and Moderate m/journals/jamainternal 20‐Oct‐20 RCT France Hermine et al. NCT04331808 Tocilizumab outcomes of patients hospitalized Medicine or Severe Pneumonia: A Randomized Clinical medicine/fullarticle/277 with moderate‐to‐severe COVID‐ Trial 2187 19 pneumonia Effect of Tocilizumab vs Standard Care on https://jamanetwork.co NCT04346355; JAMA Internal Clinical Worsening in Patients Hospitalized m/journals/jamainternal To evaluate the effect of early 20‐Oct‐20 RCT Italy Salvarani et al. EudraCT Identifier: Tocilizumab Medicine With COVID‐19 PneumoniaA Randomized medicine/fullarticle/277 tocilizumab administration 2020‐001386‐37. Clinical Trial 2186 International Journal of https://pharmascope.org To evaluate the efficacy of Efficacy of umifenovir in the treatment of Randomized 01‐Oct‐20 Research in Kyrgizstan Yethindra et al. /ijrps/article/view/2839/ NA Umifenovir umifenovir in mild and moderate mild and moderate covid‐19 patients clinical study Pharmaceutical 6116 COVID‐19 patients Sciences https://www.nejm.org/d To evaluate the efficacy of Remdesivir for the Treatment of Covid‐19 — remdesivir in shortening time to 8 October 2020 NEJM RCT USA John H. Beigel, et al. oi/10.1056/NEJMoa2007 NCT04280705 Remdesivir Final Repor recovery in hospitalized COVID‐19 764 patients. Safety and immunogenicity of an inactivated https://www.sciencedire To assess the safety and SARS‐CoV‐2 vaccine, BBIBP‐CorV: a Phase 1/2 ct.com/science/article/pi 15 October 2020 Lancet China Shengli Xia, et al. ChiCTR2000032459. BBIBP‐CorV immunogenicity of an inactivated randomised, double‐blind, placebo‐ vaccine trial i/S1473309920308318?v SARS CoV2 vaccine controlled, phase 1/2 trial ia%3Dihub https://www.medrxiv.or Lopinavir/ritonavir, Repurposed antiviral drugs for COVID‐19 remdesivir, Are repurposed andiviral drugs 15 October 2020 MedRiXV RCT International Hongchao Pan, et al. g/content/10.1101/2020 ISRCTN83971151 –interim WHO SOLIDARITY trial results hydroxychloroquine, effective in treating COV ID19? .10.15.20209817v1 interferon To assess the safety and dose https://www.nejm.org/d response through reduction of SARS‐CoV‐2 Neutralizing Antibody LY‐ Monoclonal antibody, LY‐ 28 October 2020 NEJM Phase 2 RCT USA Peter Chen, et al. oi/10.1056/NEJMoa2029 NCT04427501 viral load of monoclonal antibody CoV555 in Outpatients with Covid‐19 CoV555 849 LY‐CoV555 in patients with mild or moderate COVID‐19

To assess if a simple incentive to self‐prone for a maximum of 12 h Self‐Proning in COVID‐19 Patients on Low‐ https://papers.ssrn.com/ per day would decrease oxygen 21 October 2020 Lancet preprint Flow Oxygen Therapy: A Cluster Randomised RCT Switzerland Aileen Kharat, et al. sol3/papers.cfm?abstract SNCTP000003718 Self‐proning needs in patients admitted for Controlled Trial _id=3692538 COVID‐19 pneumonia on low‐flow oxygen therapy. International Interim analysis of an open‐label randomized https://onlinelibrary.wile To assess if nasal irrigation can 11 September Forum of controlled trial evaluating nasal irrigations in reduce symptoms and viral RCT USA Kyle S. Kimura, et al. y.com/doi/10.1002/alr.2 NA Nasal irrigations 2020 Allergy and non‐hospitalized patients with coronavirus shedding in mild and moderate Rhinology disease 2019 2703 COVID‐19 patients https://www.medrxiv.or To assess the safety and efficacy Tocilizumab in nonventilated patients of tocilizumab in patients Preprint MedRiXV RCT USA Carlos Salama, et al. g/content/10.1101/2020 NCT04372186 Tocilizumab hospitalized with Covid‐19 pneumonia hospitalized and non‐ventilated .10.21.20210203v1 with Covid‐19 pneumonia.

The use of intravenous immunoglobulin https://bmcinfectdis.bio To evaluate the efficacy of BMC Infectious gamma for the treatment of severe Naser Gharebaghi, et medcentral.com/articles/ IRCT2020050104725 intravenous immunoglobulin 21 October 2020 RCT Iran Immunoglobulin gamma Diseases coronavirus disease 2019: a randomized al. 10.1186/s12879‐020‐ 9N1 (IVIg) in patients with severe placebo‐controlled double‐blind clinical trial 05507‐4 COVID‐19 infection. Anti‐C5a antibody IFX‐1 (vilobelimab) https://www.thelancet.c Phase 2 study to explore the treatment versus best supportive care for 28 September Alexander P J Vlaar, et om/action/showPdf?pii= potential benefit and safety of IFX‐ Lancet patients with severe COVID‐19 (PANAMO): RCT Netherlands NCT04333420 Vilobelimab 2020 al. S2665‐ 1 (vilobelimab) in patients with an exploratory, open‐label, phase 2 severe COVID‐19. randomised controlled trial 9913%2820%2930341‐6 https://www.nejm.org/d Is the SARS CoV‐2 mRNA 1273 29 September Safety and Immunogenicity of SARS‐CoV‐2 Vaccine trial Evan J. Anderson, et safe and well tolerated in older NEJM USA oi/full/10.1056/NEJMoa2 NCT04283461 mRNA‐1273 vaccine 2020 mRNA‐1273 Vaccine in Older Adults Phase 1 al. adults and does it ellicit an 028436 immune response? 30 September https://www.nature.com Does the BNT162b1 vaccine elicit COVID‐19 vaccine BNT162b1 elicits human Vaccine trial 2020 ‐pre‐ Nature Germany Ugur Sahin, et al. /articles/s41586‐020‐ NCT04380701 BNT162b1 vaccine both antibody and T‐cell response antibody and TH1 T‐cell responses Phase 1 and 2 approved 2814‐7 in healthy adults? https://assets.researchsq To evaluate the efficacy and safety of recombinant super‐ Engineered interferon alpha effectively uare.com/files/rs‐ Research Engineered interferon compound interferon versus Preprint improves clinical outcomes of COVID‐19 RCT China Chuan Li, et al. 65224/v1/22886bf0‐ ChiCTR2000029638 Square alpha traditional interferon alpha in patients ce06‐4d42‐aeb6‐ patients with moderate to severe c73ebb7c2003.pdf COVID‐19 https://www.sciencedire To evaluate the efficacy and International Interferonβ‐1b in treatment of severe COVID‐ ct.com/science/article/pi IRCT2010022800344 safety of interferon (IFN) β‐1b in 24 August 2020 Immunopharm RCT Iran Hamid Rahmani, et al. Interferon β‐1b 19: A randomized clinical trial i/S1567576920323304?v 9N27 the treatment of patients with acology ia%3Dihub severe COVID‐19 To evaluate the efficacy of https://jamanetwork.co hydroxychloroquine to prevent Efficacy and Safety of Hydroxychloroquine vs transmission of SARS‐CoV‐2 in 30 September Benjamin S Abella, et m/journals/jamainternal JAMA Placebo for Pre‐exposure SARS‐CoV‐2 RCT USA NCT04329923 Hydroxychloroquine hospital‐based HCWs with 2020 al. medicine/fullarticle/277 Prophylaxis Among Health Care Workers exposure to patients with COVID‐ 1265 19 using a pre‐exposure prophylaxis strategy Drug treatments for covid‐19: living To compare the effects of 4 September Systematic International Reed AC Siemieniuk, https://www.bmj.com/c BMJ systematic review and NA All treatments treatments for coronavirus 2020 review collaboration et al. ontent/370/bmj.m2980 network meta‐analysis disease 2019 (covid‐19). To compare the rate of clinical improvement among patients Effect of remdesivir on patients with COVID‐ https://www.ncbi.nlm.ni with COVID‐19 who received 5‐ 15‐Oct Virus Research 19: A network meta‐analysis of randomized Meta‐analysis USA, Japan Yokoyama et al. h.gov/pmc/articles/PMC N/A Remdesivir day course of remdesivir versus control trials 7437510/pdf/main.pdf 10‐day course of remdesivir versus standard care. To investigate the safety and https://www.medrxiv.or immunogenicity of an inactivated An in‐depth investigation of the safety and viral vaccine in immunized g/content/10.1101/2020 06‐Sep MedRxiv immunogenicity of an inactivated 2 SARS‐ Phase 1 RCT China Pu et el. NCT04412538 Vaccine individuals in a phase I trial, .09.27.20189548v1.full.p CoV‐2 vaccine especially focusing on safety with df regard to the immunopathology of the vaccine. Clearing the fog: Is Hydroxychloroquine https://www.medrxiv.or To assess the efficacy of HCQ in effective in reducing Corona virus disease‐ Mehmood Kamran et g/content/10.1101/2020 11‐Oct MedRxiv RCT Pakistan NCT04491994 Hydroxychloroquine reducing disease progression in 2019 progression: A randomized controlled al. .07.30.20165365v2.full.p mild COVID‐19 trial df

Lopinavir–ritonavir in patients admitted to https://www.thelancet.c Whether lopinavir–ritonavir hospital with COVID‐19 (RECOVERY): a Horby et al. om/action/showPdf?pii= ISRCTN 50189673, improves outcomes in patients 05‐Oct‐20 The Lancet RCT UK lopinavir/ritonavir randomised, controlled, open‐label, platform (RECOVERY GROUP) S0140‐ NCT04381936 admitted to hospital with COVID‐ trial 6736%2820%2932013‐4 19

An open‐label, randomized trial of the https://www.sciencedire EClinicalMedici combination of IFN‐kappa plus TFF2 with ct.com/science/article/pi Efficacy and safety of IFN‐κ and 20‐Sep‐20 RCT China Fu et al. ChiCTR2000030262 IFN‐κ , TFF2 ne standard care in the treatment of patients i/S2589537020302911?v TFF2 in COVID patients. with moderate COVID‐19 ia%3Dihub Vaccine: non‐replicating Safety and immunogenicity of the https://www.medrxiv.or adenovirus 26 based To evaluate the efficacy of a single Ad26.COV2.S COVID‐19 vaccine candidate: Phase 1/2a Netherlands, g/content/10.1101/2020 vector expressing the 25‐Sep MedRxiv Sadoff et al. NCT04436276 vaccination of 5x1010 vp of interim results of a phase 1/2a, double‐blind, RCT Belgium, USA .09.23.20199604v1.full.p stabilized pre‐fusion Ad26.COV2.S randomized, placebo‐controlled trial df spike protein of SARS‐ CoV‐2 https://www.medrxiv.or To determine the effectiveness of Hydroxychloroquine as pre‐exposure hydroxychloroquine as pre‐ g/content/10.1101/2020 21‐Sep MedRxiv prophylaxis for COVID‐19 in healthcare RCT USA Rajasingham et al. NCT04328467 Hydroxychloroquine exposure prophylaxis in .09.18.20197327v1.full.p workers: a randomized trial healthcare workers at high‐risk of df SARS‐CoV‐2 exposure Treatment with an Anti‐CK2 Synthetic https://www.medrxiv.or IG/CIGB300I/CV/200 To explore safety and efficacy of Peptide Improves Clinical 3 Response in g/content/10.1101/2020 Anti‐CK2 Synthetic 22‐Sep MedRxiv RCT Cuba Cruz et al. 1, ATENEA‐Co‐300 CIGB‐325, an anti‐CK2 peptide, in Covid‐19 Patients with Pneumonia. A .09.03.20187112v2.full.p Peptide, CIGB‐325 trial COVID‐19 patients. Randomized and 4 Controlled Clinical Trial df To compare the rate of clinical https://www.sciencedire improvement among patients Effect of remdesivir on patients with COVID‐ ct.com/science/article/pi with COVID‐19 who received 5‐ 15‐Oct Virus Research 19: A network meta‐analysis of randomized Meta‐analysis USA, Japan Yujiro Yokoyama et al. N/A Remdesivir i/S0168170220310443?v day course of remdesivir versus control trials ia%3Dihub 10‐day course of remdesivir versus standard care. https://academic.oup.co Clinical Remdesivir for Severe COVID‐19 versus a Susan A. Olender, et m/cid/advance‐ NCT04292899 and Efficacy of remdesivir in COVID19 24 July 2020 Infectious RCT vs cohort USA Remdesivir Cohort Receiving Standard of Care al. article/doi/10.1093/cid/c EUPAS34303 patients Diseases iaa1041/5876045 Assess the efficacy of favipiravir in Antimicrobial A prospective, randomized, open‐label trial https://aac.asm.org/cont 17 November asymptomatic or mild COVID19 Agents of early versus late favipiravir in hospitalized RCT Japan Yohei Doi, et al. ent/early/2020/09/16/A jRCTs041190120 Favipiravir 2020 patients in viral clearance, and Chemotherapy patients with COVID‐19 AC.01897‐20 resolution of symptoms

Favipiravir versus other antiviral or standard Systematic https://virologyj.biomed To evaluate the efcacy and safety Dhan Bahadur 24‐Sep Virology Journal of care for COVID‐19 treatment: a rapid review & Nepal central.com/articles/10.1 N/A Favipiravir of the drug Favipiravir as a Shrestha et al. systematic review and meta‐analysis meta‐analysis 186/s12985‐020‐01412‐z treatment for COVID‐19.

Therapeutic versus prophylactic https://www.thrombosis To compare therapeutic 20 September Thrombosis anticoagulation for severe COVID‐19: A Anna Cristina Bertoldi research.com/article/S00 Enoxaparin, enoxaparin treatment to standard RCT Brazil REBEC RBR‐949z6v 2020 Research randomized phase II clinical trial Lemos, et al. 49‐3848(20)30530‐ anticoagulants prophylactic anticoagulant (HESACOVID) 2/fulltext#%20 treatment in severe COVID19

Treatment of COVID‐19 Patients with https://academic.oup.co To evaluate the efficacy and Clinical Prolonged Post‐Symptomatic Viral Shedding m/cid/advance‐ safety of leflunomide to treat Preprint Infectious RCT China Wang, et al ChiCTR 2000030058 Leflunomide with Leflunomide ‐‐ a Single‐Center, article/doi/10.1093/cid/c COVID‐19 patients with prolonged Diseases Randomized, Controlled Clinical Trial iaa1417/5909448 post‐symptomatic viral shedding. https://www.clinicalmicr To assess the effect of Effect of hydroxychloroquine with or without Clinical Systematic obiologyandinfection.co Chloroquine, chloroquine and azithromycin on the mortality of coronavirus France, 26 August 2020 Microbiology Review and Thibault Fiolet, et al. m/article/S1198‐ NA hydroxychloroquine, hydroxychloroquine with or disease 2019 (COVID‐19) patients: a Switzerland and Infection Meta‐analysis azithromycin without azithromycin on the systematic review and meta‐analysis 743X(20)30505‐ X/fulltext mortality of COVID‐19 patients To evaluate and compare Efficacy of commercial mouth‐rinses on SARS‐ https://www.medrxiv.or Chaminda Jayampath different commercial moutwash Preprint MedRxIV CoV‐2 viral load in saliva: Randomized RCT Singapore g/content/10.1101/2020 NA Mouth wash Seneviratne, et al. solutions and their effect on Control Trial in Singapore .09.14.20186494v1 reducing salivary viral load Evaluate the safety and efficacy of Early Anti‐SARS‐CoV‐2 Convalescent Plasma https://www.medrxiv.or María Elvira Balcells, convalescent plasma and compare Preprint MedRxIV in Patients Admitted for COVID‐19: A RCT Chile g/content/10.1101/2020 NCT04375098 Covalescent Plasma et al. an early vs deferred treatement Randomized Phase II Clinical Trial .09.17.20196212v1 strategy Evaluate the efficacy of Effect of bromhexine on clinical outcomes bromhexine in intensive care unit https://bi.tbzmed.ac.ir/A IRCT2020031170467 19 July 2020 Bioimpacts and mortality in COVID‐19 patients: A RCT Iran Khalil Ansarin Bromhexine (ICU) admission, mechanical rticle/bi‐23240 97N4 randomized clinical trial ventilation, and mortality in patients with COVID‐19.

https://www.tandfonline Expert Review Identify studies pertaining to The effect of antivirals on COVID‐19: a Systematic .com/doi/abs/10.1080/1 12‐Sep‐20 of Anti‐Infective Hussain et al. UK NA Antivirals antivirals in COVID‐19 patients systematic review review 4787210.2021.1823832? Therapy and review the clinical outcomes journalCode=ierz20

Double‐blind, randomized, placebo‐ https://academic.oup.co Clinical To determine whether NAC in 23 September controlled trial with N‐acetylcysteine for Julio Cesar Garcia de m/cid/advance‐ Infectious RCT Brazil high doses can avoid respiratory 2020 treatment of severe acute respiratory Alencar, et al. article/doi/10.1093/cid/c Diseases failure in patients with Covid‐19. syndrome caused by COVID‐19 iaa1443/5910353 Intravenous methylprednisolone pulse as a https://erj.ersjournals.co European treatment for hospitalised severe COVID‐19 m/content/early/2020/0 IRCT2020040404694 Is methylprednisolone effective in 17‐Sep‐20 Respiratory RCT Iran Edalatifard et al. Methylprednisolone patients: results from a randomised 9/09/13993003.02808‐ 7N1 treatment of COVID‐19 patients? Journal controlled clinical trial 2020 Interventions for treatment of COVID‐19: A https://journals.plos.org/ living systematic review with meta‐analyses plosmedicine/article?id= Effects of all treatment 17‐Sep‐20 Plos Medicine Meta‐analysis Denmark Juul et al. NA NA and trial sequential analyses (The LIVING 10.1371/journal.pmed.1 interventions for COVID‐19 Project) 003293

Safety and immunogenicity of an rAd26 and https://www.sciencedire rAd5 vector‐based heterologous prime‐boost Safety and immunogenicity of two ct.com/science/article/pi NCT04436471 and 04‐Sep‐20 The Lancet COVID‐19 vaccine in two formulations: two CT Russia Logunov et al. vaccine formulations (frozen and i/S0140673620318663?v NCT04437875 open, non‐randomised phase 1/2 studies lyophilised) of vaccine from Russia ia%3Dihub International https://www.sciencedire Safety and effectiveness of azithromycin in Can therapy with HCQ+AZM Journal of ct.com/science/article/pi 01‐Oct‐20 patients with COVID‐19: An open‐label RCT Iran Sekhavati et al. NA azithromycine reduce the hospital length of stay Antimicrobial i/S0924857920303411?v randomised trial in COVID‐19 patients? Agents ia%3Dihub Do increased peripheral blood Effect of Recombinant Human Granulocyte https://jamanetwork.co leukocyte and lymphocyte cell Colony–Stimulating Factor for Patients With m/journals/jamainternal 10‐Sep‐20 JAMA RCT China Cheng et al. ChiCTR2000030007 G‐CSF counts lead to clinical Coronavirus Disease 2019 (COVID‐19) and medicine/fullarticle/277 improvement in patients with Lymphopenia: A Randomized Clinical Trial 0680 COVID‐19? Azithromycin in addition to standard of care https://www.thelancet.c versus standard of care alone in the Would azithromycine improve om/action/showPdf?pii= 04‐Sep‐20 The Lancet treatment of patients admitted to the RCT Brazil Furtado et al. NCT04321278 azithromycine clinical outcomes to COVID‐19 S0140‐ hospital with severe COVID‐19 in Brazil patiets? (COALITION II): a randomised clinical trial 6736%2820%2931862‐6

Is the use of CQ or HCQ effective Journal Chloroquine and Hydroxychloroquine for the https://link.springer.com and safe in reducing mortality and Genenral Systematic Arunmozhimaran Chloroquine, 03‐Sep‐20 Treatment of COVID‐19: a Systematic Review India /article/10.1007/s11606‐ NA improving the clinical course, Internal review Elavarasi, et al. hydroxychloroquine and Meta‐analysis fever remission, and virologic Medicine 020‐06146‐w clearance in COVID‐19 patients?

Diabetes & Metabolic https://www.sciencedire No benefit of hydroxychloroquine in COVID‐ November ‐ Syndrome: Systematic ct.com/science/article/pi Is HCQ effective in milde to 19: Results of Systematic Review and Meta‐ India Pathak et al. NA hydroxychloroquine December 2020 Clinical review i/S1871402120303362?v moderate COVID‐19 patients? Analysis of Randomized Controlled Trials" Research & ia%3Dihub Reviews Naunyn‐ Hydroxychloroquine use and progression or https://link.springer.com Schmiedeberg's Systematic Benefits and harms of HCQ in 06‐Sep‐20 prognosis of COVID‐19: a systematic review China Zang et al /article/10.1007%2Fs002 NA hydroxychloroquine Archives of review COVID‐19 patients and meta‐analysis Pharmacology 10‐020‐01964‐5 https://jamanetwork.co m/journals/jama/fullartic Effect of Dexamethasone on Days Alive and le/2770277?utm_campai To determine whether Ventilator‐Free in Patients With Moderate or intravenous dexamethasone Bruno M. Tomazini, et gn=articlePDF&utm_med 02‐Sep‐20 JAMA Severe Acute Respiratory Distress Syndrome RCT Brazil NCT04327401 Dexamethasone increases the number of ventilator‐ al. ium=articlePDFlink&utm and COVID‐19 The CoDEX Randomized free days among patients with Clinical Trial _source=articlePDF&utm COVID‐19–associated ARDS. _content=jama.2020.170 21 https://jamanetwork.co m/journals/jama/fullartic To estimate the association Association Between Administration of le/2770279?utm_campai between administration of Systemic Corticosteroids and Mortality International gn=articlePDF&utm_med PROSPERO database 02‐Sep‐20 JAMA Meta‐analysis Jonathan A.C., et al. Corticosteroids corticosteroids compared with Among Critically Ill Patients With COVID‐19 ‐ Collaboration ium=articlePDFlink&utm (CRD42020197242) usual care or placebo and 28‐day A Meta‐analysis _source=articlePDF&utm all‐cause mortality. _content=jama.2020.170 23 https://jamanetwork.co m/journals/jama/fullartic Effect of Hydrocortisone on 21‐Day Mortality le/2770276?utm_campai Does low‐dose hydrocortisone or Respiratory Support Among Critically Ill Pierre‐François gn=articlePDF&utm_med decrease treatment failure in 02‐Sep‐20 JAMA RCT France NCT02517489 Hydrocortisone Patients With COVID‐19 ‐ A Randomized Dequin, et al. ium=articlePDFlink&utm patients with COVID‐19–related Clinical Trial _source=articlePDF&utm acute respiratory failure? _content=jama.2020.167 61 https://jamanetwork.co m/journals/jama/fullartic Effect of Hydrocortisone on Mortality and le/2770278?utm_campai To determine whether Organ Support in Patients With Severe gn=articlePDF&utm_med hydrocortisone improves outcome 02‐Sep‐20 JAMA COVID‐19 The REMAP‐CAP COVID‐19 RCT UK Derek C. Angus, et al. NCT02735707 Hydrocortisone ium=articlePDFlink&utm for patients Corticosteroid Domain Randomized Clinical with severe COVID‐19. Trial _source=articlePDF&utm _content=jama.2020.170 22 Convalescent plasma in the management of Anup Agarwal et al. To assess the effectiveness of moderate COVID‐19 in India: An open‐label https://www.bmj.com/c CTRI/2020/04/0247 12 October 2020 BMJ RCT India and PLACID Convalescent plasma Convalescent plasma for the parallel‐arm phase II multicentre randomized ontent/371/bmj.m3939 75 Collaborators treatment of COVID‐19 controlled trial (PLACID Trial)

To demonstrate the efficacy and https://www.medrxiv.or safety of Convalescent Plasma Convalescent Plasma for COVID‐19: A g/content/10.1101/2020 used to prevent progression to 01‐Sep MedRxiv RCT Spain Avendaño‐Solà et al. NCT04345523 Convalescent plasma multicenter, randomized clinical trial .08.26.20182444v3.full.p severe disease or death in df hospitalized patients with earlier forms of COVID‐19 Gargling with 1% https://www.medrxiv.or To assess the ability of regular Early viral clearance among COVID‐19 povidone‐iodine Nurul Azmawati g/content/10.1101/2020 gargling to eliminate SARS‐CoV‐2 09‐Sep MedRxiv patients when gargling with Povidone‐Iodine RCT Malaysia NCT04410159 (Betadine®), essential Mohamed et al. .09.07.20180448v1.full.p in the oropharynx and and Essential oils ‐ a clinical trial. oils (Listerine®) or tap nasopharynx. df water https://www.medrxiv.or To investigate whether Tocilizumab in Hospitalized Patients With g/content/10.1101/2020 tocilizumab has clinical benefit in 12/09/2020 MedRxiv RCT USA Rosas et al. NCT04320615 Tocilizumab COVID‐19 Pneumonia .08.27.20183442v2.full.p hospitalized patients with severe df COVID‐19 pneumonia. https://www.sciencedire Efficacy and safety of triazavirin therapy for ct.com/science/article/pi To assess the efficacy of 08‐Sep Engineering coronavirus disease 2019: A pilot RCT China Wu et al. ChiCTR20000300001 Triazavirin i/S2095809920302411?v Triazavirin (TZV) for Covid‐19 randomized controlled trial ia%3Dihub To evaluate the efficacy of Patient‐Reported Health Outcomes After https://assets.researchsq treatment with intravenous Treatment of COVID‐19 with Nebulized uare.com/files/rs‐ and/or nebulized neutral BMC Infectious and/or Intravenous Neutral Electrolyzed neutral electrolyzed 10‐Sep RCT Cuba Delgado‐Enciso et al. 68403/v1/e14a5067‐ RPCEC00000309 electrolyzed saline combined with Diseases. Saline Combined with Usual Medical Care saline usual medical care versus usual Versus Usual Medical care alone: A cd36‐4094‐9c29‐ medical care alone, in ambulatory Randomized, Open‐Label, Controlled Trial. 4bb66ac46805.pdf patients with COVID‐19. https://www.sciencedire Computers in Prediction of respiratory decompensation in ct.com/science/article/pi 01‐Sep‐20 Biology and Covid‐19 patients using machine learning: RCT USA Burdick et al. NCT04390516 NA NA i/S0010482520302845?v Medicine The READY trial ia%3Dihub Journal of Effectiveness of remdesivir for the treatment https://onlinelibrary.wile 19‐Aug‐20 Medical of hospitalized Covid‐19 persons: a network Review China Jiang et al. y.com/doi/abs/10.1002/j NA Remdesivir Remdesivir and its clinical effect Virology meta‐analysis mv.26443

Sofosbuvir and daclatasvir compared with https://academic.oup.co Journal of standard of care in the treatment of patients m/jac/advance‐ IS sofosbuvir and dalatasvir 19‐Aug‐20 Antimicrobial admitted to hospital with moderate or RCT Iran Sadeghi et al. IRCT2020012804629 sofosbuvir/daclatasvir article/doi/10.1093/jac/d effective in COVID patients? Chemotherapy severe coronavirus infection (COVID‐19): a 4N2 randomized controlled trial kaa334/5889948

https://stemcellres.biom Are human umbilical cord Stem Cell Treatment of severe COVID‐19 with human edcentral.com/articles/1 umbilical cord mesenchymal stem cell infusion 18‐Aug‐20 Research & RCT China Shu et al. ChiCTR2000031494 umbilical cord mesenchymal stem cells 0.1186/s13287‐020‐ mesenchymal stem cells effective and safe for the Therapy 01875‐5 treatment of severe COVID? "Effect of Calcifediol Treatment and best Journal of Evaluate the effect of calcifediol Available Therapy versus best Available https://www.sciencedire Steroid on ICU admission and mortality Therapy on Intensive Care Unit Admission Marta Entrenas ct.com/science/article/pi October Biochemistry RCT Spain NCT04366908 Calcifediol among patients hospitalized for and Mortality Among Patients Hospitalized Castillo, et al. i/S0960076020302764?v and Molecular COVID‐19 for COVID‐19: A Pilot Randomized Clinical Biology ia%3Dihub study Effect of an Inactivated Vaccine Against SARS‐ https://jamanetwork.co To assess the safety and CoV‐2 on Safety and Immunogenicity Vaccine ‐ 13 August 2020 JAMA China Shengli Xia, et al. m/journals/jama/fullartic ChiCTR2000031809 Inactivated vaccine immunogenicity of this whole Outcomes Interim Analysis of 2 Randomized Phase I and II virus inactivated vaccine Clinical Trials le/2769612 Effect of Remdesivir vs Standard Care on https://jamanetwork.co Christoph D. Spinner, Effect of remdesivir in patients 21 August 2020 JAMA Clinical Status at 11 Days in Patients With RCT USA m/journals/jama/fullartic NCT04292730 Remdesivir et al. with moderate COVID19 Moderate COVID‐19 le/2769871 Drug treatments for covid‐19: living Systematic International Reed AC Siemieniuk, https://www.bmj.com/c Living systematic review and 30 July 2020 BMJ systematic review and network meta‐ NA All treatments Review Collaboration et al. ontent/370/bmj.m2980 network meta‐analysis analysis https://www.medrxiv.or To assess the safety and Vaccine: RNA vaccines RNA‐Based COVID‐19 Vaccine BNT162b2 g/content/10.1101/2020 immunogenicity of varying dose 28‐Aug MedRXiv RCT USA/ Germany Walsh et al. NCT04368728 BNT162b1 and Selected for a Pivotal Efficacy Study .08.17.20176651v2.full.p levels of vaccines BNT162b1 and BNT162b2 df BNT162b2. Methylprednisolone as Adjunctive Therapy https://academic.oup.co Clinical Assess the efficacy of short‐term for Patients Hospitalized With COVID‐19 Christiane Maria m/cid/advance‐ 12 August 2020 Infectious RCT Brazil NCT04343729 Methylprednisolone methylprednisolone in patients (Metcovid): A Randomised, Double‐Blind, Prado Jeronimo, et al. article/doi/10.1093/cid/c Diseases with COVID‐19 Phase IIb, Placebo‐Controlled Trial iaa1177/5891816 Assess the efficacy and safety of AVIFAVIR for Treatment of Patients with https://academic.oup.co Clinical favipiravir in moderate COVID19 Moderate COVID‐19: Interim Results of a Andrey A. m/cid/advance‐ 09 August 2020 Infectious RCT Russia NCT04434248 Favipiravir and select the optimal dosing Phase II/III Multicenter Randomized Clinical Ivashchenko, et al. article/doi/10.1093/cid/c Diseases regimen for further evaluation Trial iaa1176/5890024 (Phase III). International https://www.sciencedire SARS‐CoV‐2 Clearance in COVID‐19 Patients Efficacy of Novaferon and Journal of ct.com/science/article/pi Preprint with Novaferon Treatment: A Randomized, China Fang Zheng, et al. ChiCTR2000029496 Novaferon Novaferon + Lopinavir/ritonavir in Infectious i/S120197122030597X?v Open‐label, Parallel Group Trial moderate and severe COVID19. Diseases ia%3Dihub Telmisartan for treatment of Covid‐19 https://www.medrxiv.or Assess the anti‐inflammatory Preprint medRxiv patients: an open randomized clinical trial. RCT Argentina Mariano Duarte, et al. g/content/10.1101/2020 NCT04355936 Telmisartan effect of telmisartan in COVID‐19 Preliminary report. .08.04.20167205v2 patients Auxora versus standard of care for the https://ccforum.biomedc treatment of severe or critical COVID‐19 Safety and tolerability of auxora in 14 August 2020 Critical Care RCT USA Joseph Miller, et al. entral.com/articles/10.1 NCT04345614. Auxora pneumonia: results from a randomized severe or critical COVID‐19 controlled trial 186/s13054‐020‐03220‐x Immunogenicity and Safety of a SARS‐CoV‐2 Inactivated Vaccine in Healthy Adults Aged https://www.medrxiv.or Phase II Is this SARS CoV 2 inactivated Preprint medRxiv 18‐59 years: Report of the Randomized, China Yanjun Zhang, et al. g/content/10.1101/2020 NCT04352608 Inactiviated Vaccine vaccine RCT vaccine safe and well tolerated? Double‐blind, and Placebo‐controlled Phase .07.31.20161216v1 2 Clinical Trial Beneficial effects of colchicine for moderate https://www.medrxiv.or To evaluate the efficacy of to severe COVID‐19: an interim analysis of a Preprint medRxiv RCT Brazil Maria IF Lopes, et al. g/content/10.1101/2020 RBR‐8jyhxh Colchicine colcihcine in treating severe and randomized, double‐blinded, placebo moderate COVID‐19 controlled clinical trial .08.06.20169573v2

Phase 1–2 Trial of a SARS‐CoV‐2 https://www.nejm.org/d NVX‐CoV2373; Assess the safety and tolerability 2 September Phase I NEJM Recombinant Spike Protein Nanoparticle Australia Cheryl Keech, et al. oi/full/10.1056/NEJMoa2 NCT04368988 recombinant of the NVX‐COV2373 recombinant 2020 vaccine RCT Vaccine 026920 nanoparticle vaccine vaccine in healthy subjects. https://www.nejm.org/d Asses the efficacy of Hydroxychloroquine with or without Alexandre B. hydroxychloroquine with and 23 July 2020 NEMJ RCT Brazil oi/10.1056/NEJMoa2019 NCT04322123 Hydroxychloroquine Azithromycin in Mild‐to‐Moderate Covid‐19 Cavalcanti, et al. without azithromycin in mild to 014 moderate COVID19 Hydroxychloroquine, Journal of Systematic Review and Meta‐analysis of Viveksandeep https://onlinelibrary.wile Tocilizumab, Remdesivir, Asses overall efficacy of Systematic 6 July 2020 Medical Effectiveness of Treatment Options Against USA Thoguluva y.com/doi/epdf/10.1002 NA convalescent plasma, treatments that have been review Virology SARS‐CoV‐2 infection Chandrasekar, et al. /jmv.26302 steroids, studied thus far. lopinavir/ritonavir

Use of a humanized anti‐CD6 monoclonal https://www.medrxiv.or Is itolizumab a safe and efficient Preprint medRxiv antibody (itolizumab) in elderly patients with CT Cuba Yayquier Díaz, et al. g/content/10.1101/2020 RPCEC00000311 Itolizumab treatment for COVID 19 in moderate COVID‐19 .07.24.20153833v1 elderley patients? https://www.medrxiv.or Is bevacizumab a safe and Efficacy and tolerability of bevacizumab in Preprint medRxiv CT China, Italy Jiaojiao Pang, et al g/content/10.1101/2020 NCT04275414 Bevacizumab efficient treatment for severe patients with severe Covid ‐19 .07.26.20159756v1 COVID 19? A clinical pilot study on the safety and https://www.sciencedire To evaluate the efficacy and EClinicalMedici efficacy of aerosol inhalation treatment of safety of intranasal inhalation of 29 July 2020 CT China + USA Weihui et al. ct.com/science/article/pi ChiCTR2000030262 IFN‐κ plus trefoil factor 2 ne (Lancet) IFN‐κ plus TFF2 in patients with moderate TFF2 and IFN‐κ protein for SARS‐ COVID‐19 i/S2589537020302224 CoV‐2 infection

A Small‐Scale Medication of Leflunomide as a https://link.springer.com Virologica Is leflunomide effective in COVID‐ 21 July 2020 Treatment of COVID‐19 in an Open‐Label CT China Hu et al. /article/10.1007%2Fs122 ChiCTR 2000030058 leflunomide Sinica 19 patients? Blank‐Controlled Clinical Trial 50‐020‐00258‐7 To assess the immunogenicity, Safety and immunogenicity of the ChAdOx1 Folegatti et al. on https://www.thelancet.c reactogenicity, and safety of nCoV‐19 vaccine against SARS‐CoV‐2: a behalf of the Oxford om/journals/lancet/articl ISRCTN 15281137; ChAdOx1 nCoV‐19 20‐Jul Lancet RCT UK vaccination with ChAdOx1 nCoV‐ preliminary report of a phase 1/2, single‐ COVID Vaccine Trial e/PIIS0140‐ NCT04324606 vaccine 19 in single‐dose and two‐dose blind, randomised controlled trial Group 6736(20)31604‐4/fulltext regimens.

Immunogenicity and safety of a recombinant https://www.thelancet.c Phase 2 trial to further evaluate adenovirus type‐5‐vectored COVID‐19 adenovirus type‐5 (Ad5)‐ the immunogenicity and safety in om/action/showPdf?pii= 20‐Jul Lancet vaccine in healthy adults aged 18 years or RCT China Feng‐Cai Zhu et al. NCT04341389 vectored COVID‐19 a larger population, and to S0140‐ older: a randomised, double‐blind, placebo‐ vaccine determine an appropriate dose controlled, phase 2 trial 6736%2820%2931605‐6 for the efficacy study

https://www.nature.com To assess safety, tolerability, and Phase 1/2 study of COVID‐19 RNA vaccine Phase 1/2 immunogenicity of RNA Vaccine 12 August 2020 Nature USA/Germany Mulligan et al. /articles/s41586‐020‐ NCT04368728 RNA Vaccine BNT162b1 BNT162b1 in adults trial candidate in a dose escalation 2639‐4 study among healthy adults.

https://www.medrxiv.or To complement previous reported Concurrent human antibody and TH1 type T‐ NCT04380701, data by providing a detailed Phase 1/2 g/content/10.1101/2020 20‐Jul‐20 Medrxiv cell responses elicited by a COVID‐19 RNA Germany/ USA Sahin et al. EudraCT: 2020‐ RNA Vaccine BNT162b1 characterisation of antibody and trial .07.17.20140533v1.full.p vaccine 001038‐36 T76 cell immune responses df elicited by BNT162b1 vaccination. https://www.nejm.org/d To evaluate the safety and An mRNA Vaccine against SARS‐CoV‐2 — 14‐Jul NEMJ Phase 1 trial USA Jackson et al. oi/pdf/10.1056/NEJMoa NCT04283461 mRNA‐1273 vaccine immunogenicity of mRNA‐1273 Preliminary Report 2022483 vaccine Effect of Hydroxychloroquine in Hospitalized Horby et al. https://www.nejm.org/d To assess the safety and efficacy Patients with COVID‐19: Preliminary results ISRCTN 50189673, 08‐Oct NEJM RCT UK (RECOVERY oi/10.1056/NEJMoa2022 Hydroxychloroquine of hydroxychloroquine in patients from a multi‐centre, randomized, controlled NCT04381936 Collaborative Group) hospitalized with COVID‐19 trial. 926 A Multicenter, randomized, open‐label, controlled trial to evaluate the efficacy and https://www.medrxiv.or RCT & To evaluate HCQ efficacy and tolerability of hydroxychloroquine and a g/content/10.1101/2020 10‐Jul Medrxiv retrospective Taiwan Cheng‐Pin Chen et al. NCT04384380 Hydroxychloroquine tolerability in adult patients with retrospective study in adult patients with .07.08.20148841v1.full.p cohort study mild to moderate COVID‐19. mild to moderate Coronavirus disease 2019 df (COVID‐19) To investigate whether Annals of Hydroxychloroquine in Nonhospitalized https://www.acpjournals hydroxychloroquine could reduce 16‐Jul Internal Adults With Early COVID‐19 ‐ A Randomized RCT USA Skipper et al. .org/doi/10.7326/M20‐ NCT04308668 Hydroxychloroquine COVID‐19 severity in adult Medicine Trial 4207 outpatients Is early treatment with Hydroxychloroquine Alone or in Combination https://papers.ssrn.com/ hydroxychloroquine (HCQ) with with Cobicistat‐Boosted Darunavir for Hydroxychloroquine, our without cobicistat/darunavir Preprint Lancet RTC Spain Mitjà et al, sol3/papers.cfm?abstract NCT04304053 Treatment of Mild COVID‐19: A Cluster‐ Darunavir, Cobicistat more efficacious than no‐ Randomized Clinical Trial _id=3615997 treatment for outpatients with mild Covid‐19? https://assets.researchsq To assess the effcacy and safety of hydroxychloroquine therapy on A pragmatic randomized controlled trial uare.com/files/rs‐ Magnus Nakrem SARS‐CoV‐2 oropharyngeal viral Preprint ResearchSquare reports the efficacy of hydroxychloroquine RCT Norway 44055/v1/3fb11155‐ NCT04316377 Hydroxychloroquine Lyngbakken, et al. kinetics in patients hospitalized on coronavirus disease 2019 viral kinetics d83c‐48a0‐ae74‐ with moderately severe COVID‐ b3cce9a5eac3.pdf 19. Evaluate the antiviral activity and Open Forum Antiviral Activity and Safety of https://pubmed.ncbi.nlm safety of darunavir/cobicistat 11 June 2020 Infectious Darunavir/Cobicistat for the Treatment of RCT China Jun Chen, et al. NCT04252274 Darunavir, Cobicistat .nih.gov/32671131/ (DRV/c) for treating mild COVID‐ Diseases COVID‐19 19 lopinavir/ritonavir; SN arbidol; Systematic https://link.springer.com To assess the current evidence Comprehensive Systematic and Statistical Review of hydroxychloroquine; 15‐Jul‐20 review & USA Juan A. Siordia Jr et al. /article/10.1007%2Fs423 N/A regarding human controlled Clinical Coronavirus Disease 19 Treatment Trials remdesivir; tocilizumab; Meta‐analysis COVID‐19 treatment trials. Medicine 99‐020‐00399‐6 favipiravir; heparin; dexamethasone

https://www.researchgat e.net/profile/Abu_Taiub _Mohammed_Mohiuddi n_Chowdhury2/publicati on/342159343_A_comp arative_observational_st udy_on_Ivermectin‐ Compared outcomes of Ivermectin‐Doxycycline vs. Abu Taiub _Doxycycline_and_Hydro A Randomized Trial of Ivermectin‐ Ivermectin, Doxycycline, Hydroxychloroquine‐Azithromycin BMC Infectious Mohammed xychloroquine‐ Preprint Doxycycline and Hydroxychloroquine‐ RT Bangladesh NCT04434144 Hydroxychloroquine, combination therapy COVID19 Diseases Mohiuddin Azithromycin_therapy_o Azithromycin therapy on COVID19 patients. Azithromycin patients with mild to moderate Chowdhury, et al. n_COVID19_patients/link disease. s/5f02954c92851c52d61 9d95e/A‐comparative‐ observational‐study‐on‐ Ivermectin‐Doxycycline‐ and‐Hydroxychloroquine‐ Azithromycin‐therapy‐on‐ COVID19‐patients.pdf

https://www.cochranelib Assess the effectiveness of Convalescent plasma or hyperimmune Convalescent plasma, updated Systematic International rary.com/cdsr/doi/10.10 convalescent plasma and Cochrane immunoglobulin for people with COVID‐19: a Piechotta V, et al. NA hyperimmune 12/10/20 review Collaboration 02/14651858.CD013600. hyperimmune immunoglobulin for living systematic review immunoglobulin pub2/abstract treating people with COVID19

A Randomized, Open‐label, Controlled https://onlinelibrary.wile Advanced Clinical Trial of Azvudine Tablets in the Efficacy of azvudine in treating Preprint RCT China Zhigang Ren, et al. y.com/doi/epdf/10.1002 ChiCTR2000029853 Azvudine Science Treatment of Mild and Common COVID‐19, A mild COVID19 patients Pilot Study /advs.202001435 To evaluate the effect of Effect of Colchicine vs Standard Care on JAMA Network treatment with colchicine on Cardiac and Inflammatory Biomarkers and https://jamanetwork.co Open: Randomized cardiac and inflammatory 24/06/2020 Clinical Outcomes in Patients Hospitalized Greece Deftereos et al. m/journals/jamanetwork NCT04326790 Colchicine Infectious clinical trial biomarkers and clinical outcomes With Coronavirus Disease 2019The GRECCO‐ Diseases open/fullarticle/2767593 in patients hospitalized with 19 Randomized Clinical Trial COVID‐19. The Is febuxostat effective in International Febuxostat Therapy in Outpatients With https://pubmed.ncbi.nlm IRCT2019072704434 Hydroxychloroquine, 30‐Jun‐20 RCT Iran Davoodi et al. comparision with Journal of Suspected COVID‐19: A Clinical Trial .nih.gov/32603531/ N1 febuxostat hydroxychloroquine? Clinical Practice

https://www.nejm.org/d oi/pdf/10.1056/NEJMoa 2021436?casa_token=H8 Horby et al. To test the effectiveness of Effect of Dexamethasone in Hospitalized GAcaEgprUAAAAA:m_9Q ISRCTN 50189673, 17 July 2020 NEMJ RCT UK (RECOVERY Writing Dexamethasone dexamethasone in patients Patients with COVID‐19: Preliminary Report lb5FCP6d6YPLPMryKLqV NCT04381936 Committee) hospitalized with COVID‐19 P0QTUouiQsD39ki_1j8u1 syZDvAET7pLjZ3GbCpQS V4V62JZ8086BOdT

To determine whether a 6‐day https://www.medrxiv.or course of intravenous GLUCOCOVID: A controlled trial of methylprednisolone (MP) g/content/10.1101/2020 EudraCT number: 18‐Jun medRxiv methylprednisolone in adults hospitalized RCT Spain Corral‐Gudino et al. methylprednisolone improves outcome in patients .06.17.20133579v1.full.p 2020‐001934‐37 with COVID‐19 pneumonia with SARS CoV‐2 infection at risk df of developing Acute Respiratory Distress Syndrome (ARDS) https://immunology.scie Science Inhibition of Bruton tyrosine kinase in Is acalabrutinib effective in severe 05‐Jun‐20 RCT USA Roschewski et al. ncemag.org/content/5/4 NA Acalabrutinib Immunology patients with severe COVID‐19 COVID‐19 patients? 8/eabd0110 Were the non‐pharmaceutical 8 June 2020 ‐ https://www.nature.com interventions implemented in Estimating the effects of non‐pharmaceutical Non‐pharmaceutical Accelerated Nature Modelling UK Seth Flaxman, et al. /articles/s41586‐020‐ NA European countries effective in interventions on COVID‐19 in Europe interventions publication 2405‐7 limiting the spread of SARS CoV‐ 2? The Janus kinase 1/2 inhibitor ruxolitinib in https://www.nature.com Nature ‐ Retrospective Efficacy and safety of ruxolitinib in 8 May 2020 COVID‐19 with severe systemic Germany F. La Rosée, et al. /articles/s41375‐020‐ Ruxolitinib Leukemia analysis severe COVID19 hyperinflammation 0891‐0 https://www.sciencedire Is canakinumab a safe and Lancet Canakinumab in a subgroup of patients with Retrospective ct.com/science/article/pi 8 June 2020 Italy Claudio Ucciferri, et al. NA Canakinumab effective treatment against Reheumatology COVID‐19 analysis i/S2665991320301673?v COVID19? ia%3Dihub Use of personal protective equipment To examine the protective effects against coronavirus disease 2019 by Observational https://www.bmj.com/c 10‐Jun‐20 BMJ China Min Liu et al. NA NA of appropriate personal protective healthcare professionals in Wuhan, China: study ontent/369/bmj.m2195 equipment cross sectional study https://www.thelancet.c Effects of non‐pharmaceutical interventions om/journals/lanpub/artic What is the impact of different The Lancet Modelling 02‐Jun‐20 on COVID‐19 cases, deaths, and demand for UK Gavines et al. le/PIIS2468‐ NA NA control measures for mitigating Digital Healt study hospital services in the UK: a modelling study 2667(20)30133‐ the burden of COVID‐19 X/fulltext#%20 Clinical performance of the Luminex NxTAG Journal of https://jcm.asm.org/cont CoV Extended Panel for SARS‐CoV‐2 Jonathan Hon‐Kwan Evaluation of Luminex NxTAG in 01‐Jun‐20 Clinical Diagnostic Hong‐Kong ent/early/2020/05/29/JC NA Nucleic acid test detection in nasopharyngeal specimens of Chen COVID‐19 detection Microbiology COVID‐19 patients in Hong Kong M.00936‐20 https://www.sciencedire Clinical Clinical evidence for repurposing chloroquine Systematic Australia/Sri ct.com/science/article/pi Hydroxychloroquine, Does hydroxychloroquine have 26‐May‐20 Microbiology and hydroxychloroquine as antiviral agents: a review / Meta‐ Rodrigo et al. NA Lanka i/S1198743X20302937?v chloroquine antiviral effect? and Infection systematic review analysis ia%3Dihub To test the performance Kinetics of the humoral immune response to https://www.medrxiv.or characteristics of seven SARS‐CoV‐2: comparative analytical g/content/10.1101/2020 14‐Jun MedRxiv Diagnostic Belgium Herroelen et al. N/A Antibody test commercially available serology performance of seven commercial serology .06.09.20124719v2.full.p tests for detection of antibodies tests df against the SARS‐CoV‐2 https://www.medrxiv.or To assess the therapeutic efficacy Therapeutic effectiveness of interferon‐alpha observational g/content/10.1101/2020 09‐Jun MedRxiv Cuba Pereda et al. RPCEC00000318 Interferon alpha 2b of IFN‐α2b in patients infected 2b against COVID‐19: the Cuban experience study .05.29.20109199v1.full.p with SARS‐CoV‐2 df ICON (Ivermectin in COvid Nineteen) study: https://www.medrxiv.or To determine whether Ivermectin Use of Ivermectin is Associated with Lower Retrospective Cepelowicz Rajter et g/content/10.1101/2020 is associated with lower mortality 10‐Jun MedRxiv USA N/A Ivermectin Mortality in Hospitalized Patients with analysis al. .06.06.20124461v2.full.p rate in patients hospitalized with COVID19 df COVID‐19 To assess the efficacy of prospective https://www.medrxiv.or lenzilumab therapy in patients First Clinical Use of Lenzilumab to Neutralize study with hospitalized with severe COVID‐19 g/content/10.1101/2020 14‐Jun MedRxiv GM‐CSF in Patients with Severe and Critical FDA USA Temesgen et al. N/A Lenzilumab pneumonia, who had clinical .06.08.20125369v2.full.p COVID‐19 Pneumonia emergency and/or biomarker evidence for use IND df increased risk of progression to respiratory failure. To investigate whether soluble urokinase plasminogen activator Low levels of the prognostic biomarker https://www.medrxiv.or receptor (suPAR) can aid in suPAR are predictive of mild outcome in prospective g/content/10.1101/2020 02‐Jun MedRxiv Denmark/USA Eugen‐Olsen et al. N/A Prognostic biomarker identifying patients with low risk patients with symptoms of COVID‐19 ‐ a cohort study .05.27.20114678v1.full.p of respiratory failure when prospective cohort study df presenting with symptoms of COVID‐19. https://www.medrxiv.or To determine if Low Dose‐ Low‐Dose Whole‐Lung Radiation for COVID‐ Radiation Therapy can reduce g/content/10.1101/2020 08/06/2020 MedRxiv 19 Pneumonia: Planned Day‐7 Interim CT USA Hess et al. NCT: 04366791 Low dose radiation pulmonary inflammation .06.03.20116988v1.full.p Analysis of a Registered Clinical Trial associated with COVID‐19 df pneumonia. https://www.medrxiv.or To evaluate the safety and Efficacy and Safety of Leflunomide for g/content/10.1101/2020 efficacy of leflunomide for the 02‐Jun MedRxiv Refractory COVID‐19: An Open‐label CT China Wang et al. ChiCTR2000030058 Leflunomide .05.29.20114223v1.full.p treatment of refractory COVID‐19 Controlled Study df in adult patients. https://www.medrxiv.or To explore the effect of high fiber Nano short peptide nutrition intervention on Retrospective g/content/10.1101/2020 whey short peptide enteral 08‐Jun MedRxiv China Zhang et al. N/A enteral nutrition the prognosis of patients with COVID‐19 analysis .06.03.20083980v1.full.p nutrition on the prognosis of df patients with COVID‐19

https://www.medrxiv.or To determine if ozonated Ozone therapy for patients with SARS‐COV‐2 autohemotherapy is associated prospective Spain/ g/content/10.1101/2020 05‐Jun MedRxiv pneumonia: a single‐center prospective Hernández et al. N/A Ozone therapy with a shorter time to clinical cohort study USA/Canada .06.03.20117994v1.full.p cohort study improvement in patients with df severe COVID‐19 pneumonia.

https://www.medrxiv.or To determine the effect of Center CIGB‐258 immunomodulatory peptide: a for Genetic Engineering and Venegas‐Rodriguez et g/content/10.1101/2020 CIGB‐258 immuno‐ 02‐Jun MedRxiv novel promising treatment for critical and CT Cuba RPCEC00000313 Biotechnology (CIGB)‐258 therapy al. .05.27.20110601v1.full.p modulatory peptide severe COVID‐19 patients in seriously, or critically ill patients df with COVID‐19. To determine the clinical A cohort study to evaluate the effect of https://www.medrxiv.or outcomes of older COVID‐19 combination Vitamin D, Magnesium and Observational g/content/10.1101/2020 Vitamin D, Magnesium patients who received Vitamin D, 02‐Jun MedRxiv Singapore Chuen Wen Tan et al. N/A Vitamin B12 (DMB) on progression to severe study .06.01.20112334v1.full.p and Vitamin B12 (DMB) Magnesium and Vitamin B12 outcome in older COVID‐19 patients. df (DMB) compared to those who did not To evaluate differences in https://www.medrxiv.or morbidity and mortality among Therapeutic Anticoagulation Is Associated Retrospective g/content/10.1101/2020 mechanically ventilated patients 03‐Jun MedRxiv with Decreased Mortality in Mechanically USA Trinh et al. N/A anticoagulation agents analysis .05.30.20117929v1.full.p with COVID‐19 treated with Ventilated COVID‐19 Patients df therapeutic versus prophylactic anticoagulation

https://translational‐ EudraCT (2020‐ Tocilizumab for patients with COVID‐19 medicine.biomedcentral. 001110‐38); To evaluate efficacy of tocilizumab 21 October 2020 of Translational M CT Italy Perrone et al. Tocilizumab pneumonia. The TOCIVID‐19 phase 2 trial com/articles/10.1186/s1 clinicaltrials.gov in COVID‐19 pneumonia patients. 2967‐020‐02573‐9 (NCT04317092)

To compare SAMBA II SARS‐CoV‐2 prospective https://www.medrxiv.or performance against the standard Rapid point of care nucleic acid testing for clinical trial UK/South g/content/10.1101/2020 lab RTPCR test in suspected COVID‐ 02/06/2020 MedRxiv SARS‐CoV‐2 in hospitalised patients: a clinical and Dami Collier, et al. NCT04326387 Nucleic acid diagnostic Africa .05.31.20114520v1.full.p 19 cases presenting to hospital, trial and implementation study observational followed by a hospital‐based study df implementation study.

To compare three fully automated https://www.medrxiv.or large‐scale laboratory analyzer Side by side comparison of three fully test systems, with particular Diagnostic g/content/10.1101/2020 06‐Jun MedRxiv automated SARS‐CoV‐2 antibody assays with Austria Perkmann et al. N/A Antibody diagnostic emphasis on specificity, which is comparison .06.04.20117911v2.full.p a focus on specificity crucial for an adequate positive df predictive value given the current low seroprevalence worldwide. To describe initial experience using a commercially‐available Implementation and evaluation of a novel https://www.medrxiv.or Diagnostic multiplex two‐step nested real‐time multiplex assay for SARS‐CoV‐2: In‐ g/content/10.1101/2020 05‐Jun MedRxiv validation Australia Williams et al. N/A Nucleic acid diagnostic tandem RT‐PCR assay for the field learnings from a clinical microbiology .06.03.20117267v1.full.p study detection of coronaviruses that laboratory df infect humans, including SARS‐ CoV‐2 To construct and validate a cell‐ https://www.medrxiv.or Diagnostic for Diagnostic free assay to measure neutralizing Detection of SARS‐CoV‐2 neutralizing USA/Switzerla g/content/10.1101/2020 indentifying suitable 02‐Jun MedRxiv validation Danh et al. N/A antibodies in order to identify antibodies with a cell‐free PCR assay nd .05.28.20105692v1.full.p Convalescent plasma study suitable donors of convalescent donors df plasma

https://www.medrxiv.or To evaluate the real‐world diagnostic Diagnostic accuracy of a host response point‐ g/content/10.1101/2020 diagnostic accuracy of FebriDx for 02‐Jun MedRxiv clinical UK Clark et al. ISRCTN14966673 Diagnostic of‐care test for identifying COVID‐19 .05.27.20114512v1.full.p the identification of COVID‐19 in evaluation df hospitalised adults Alltest rapid lateral flow immunoassays is https://www.sciencedire To analyze the diagnostic Journal of reliable in diagnosing SARS‐CoV‐2 infection Diagnostic ct.com/science/article/pi August 2020 Spain García et al. NA NA performance of one serologic Clinical Virology from 14 days after symptom onset: A assay i/S1386653220302158?v rapid test in COVID‐19 patients prospective single‐center study ia%3Dihub Poor‐sleep is associated with slow recovery Effects of sleep quality on Brain, https://www.sciencedire from lymphopenia and an increased need for Retrospective recovery from lymphopenia and 06‐Jun‐20 Behaviour and China Zhang et al. ct.com/science/article/pi NA NA ICU care in hospitalized patients with COVID‐ study clinical outcomes in hospitalized Imunity 19: A retrospective cohort study i/S0889159120309946 patients with COVID‐19

To assess the overall benefit–risk of the use of remdesivir as a Remdesivir in Treatment of COVID-19: A Systematic https://doi.org/10.1007/ 28 May 2020 Drug Safety UK Miranda Davies, et al. NA Remdesivir treatment for COVID‐19 Systematic Benefit–Risk Assessment review s40264‐020‐00952‐1 compared with standard of care, placebo or other treatments

Routine Venous Thromboembolism To determine the frequency of DOI: Venous Society of Prophylaxis May Be Inadequate in the Observational Thomas K. Maatman, venous thromboembolism (VT) in 27 May 2020 USA 10.1097/CCM.00000000 NA thromboembolism Critical Care Hypercoagulable State of Severe Coronavirus study et al. critically ill COVID19 patients who prophylaxis Disease 2019 00004466 recieved prophylaxis for VT.

Effect of Convalescent Plasma Therapy on Is convalescent plasma a safe and Time to Clinical Improvement in Patients doi:10.1001/jama.2020.1 3 June 2020 JAMA RCT China Ling Li, et al. ChiCTR2000029757 Convalescent Plasma efficient treatment for severe With Severe and Life‐threatening COVID‐19 ‐ 0044 COVID19? A Randomized Clinical Trial

Journal of the https://www.sciencedire American Retrospective Ignacio J. Amat‐ ct.com/science/article/pi NCT03201185 To analyze if ramipril modifies the Preprint Ramipril in High Risk Patients with COVID‐19 Spain Ramipril College of analysis Santos, et al. i/S073510972035395X?v (source RCT) risk for COVID‐19. Cardiology ia%3Dihub

Should health care workeers wear The need of health policy perspective to https://journals.plos.org/ surgical masks or N95 respirators Systematic protect Healthcare Workers during COVID‐19 Primiano Iannone, et plosone/article?id=10.13 during the routine care (not 3 June 2020 PlosOne review / Meta‐ Italy NA N95 respirators pandemic. A GRADE rapid review on the N95 al. 71/journal.pone.023402 involving aerosol generating analysis respirators effectiveness 5 procedures) of COVID‐19 suspected or affected patients?

Investigate the effects of physical Physical distancing, face masks, and eye distance, face masks, and eye protection to prevent person‐to‐person Systematic International https://doi.org/10.1016/ PROSPERO: 1 June 2020 Lancet Derek K Chu, et al. PPE protection on virus transmission transmission of SARS‐CoV‐2 and COVID‐19: a review collaboration S0140‐6736(20)31183‐1 CRD42020177047 in health‐care and non‐health‐ systematic review and meta‐analysis care (eg, community) settings Diabetes, Exposure to DPP‐4 inhibitors and COVID‐19 Case Gian Paolo Fadini, et https://pubmed.ncbi.nlm Do DPP‐4 inhinbitors have a Preprint obesity & among people with type 2 population Italy NA DPP‐4 inhibitors al. .nih.gov/32463179/ protective effect agains COVID19? metabolism diabetes. A case‐control study study https://www.nejm.org/d A Randomized Trial of Hydroxychloroquine as Is hydroxychloroquine effective in 03 June 2020 NEJM RCT USA / Canada D.R. Boulware, et al. oi/full/10.1056/NEJMoa2 NCT04308668. Hydroxychloroquine Postexposure Prophylaxis for Covid‐19 post‐exposure prohylaxis therapy? 016638 Can CRISPR technology simplify RT‐ Biosensors and Ultra‐sensitive and high‐throughput CRISPR‐ Diagnostic https://doi.org/10.1016/j Preprint USA Zhen Huang, et al. NA CRISPR RT‐PCR PCR for SARS CoV2 and be Bioelectronics Powered COVID‐19 diagnosis assay .bios.2020.112316 effective for diagnos? Famotidine Use is Associated with Improved https://www.gastrojourn Do COVID19 patients taking Gastroenterolo Clinical Outcomes in Hospitalized COVID‐19 Retrospective Daniel E. Freedberg, Preprint USA al.org/article/S0016‐ NA Famotidine famotidine have a lower risk of gy Patients: A Propensity Score Matched study et al. intubation and/or death? Retrospective Cohort Study 5085(20)34706‐5/fulltext

International https://www.nejm.org/d Is a 5 day course of remedesivir as Remdesivir for 5 or 10 Days in Patients with collaboration/ Jason D. Goldman, et 27 May 2020 NEJM RCT oi/full/10.1056/NEJMoa2 NCT04292899 Remdesivir effective as a 10 course in treating Severe Covid‐19 Gilead al. moderately ill COVID19 patients? Sciences 015301 https://www.nejm.org/d Is remdesivir an effective Remdesivir for the Treatment of Covid‐19 — International 22 May 2020 NEJM RCT J.H. Beigel, et al. oi/full/10.1056/NEJMoa2 NCT04280705 Remdesivir treatment for reducing time to Preliminary Report collaboration 007764 recovery in COVID19 patients? Journal of Ruxolitinib in treatment of severe To evaluate the efficacy and Allergy and coronavirus disease 2019 (COVID‐19): A https://doi.org/10.1016/j ChiCTR‐OPN‐ Preprint RCT China Yang Cao, et al. Ruxolitinib safety of ruxolitinib for patients Clinical multicenter, single‐blind, randomized .jaci.2020.05.019 2000029580. with severe COVID19. Immunology controlled trial Thymosin alpha 1 (Tα1) reduces the Clinical Is thymosin alpha a safe and mortality of severe COVID 19 by restoration Retrospective https://pubmed.ncbi.nlm Preprint Infectious China Yueping Liu, et al. NA Thymosin alpha effective treatment for severe of lymphocytopenia and reversion of study .nih.gov/32442287/ Diseases COVID19? exhausted T cells International HUMAN CORONAVIRUS DATA FROM FOUR https://www.sciencedire Level of protection confered by Journal of C Raina MacIntyre, et Preprint CLINICAL TRIALS OF MASKS AND Review Australia ct.com/science/article/pi NA PPE masks and respirators for Infectious al. RESPIRATORS common coronavirus. Diseases i/S1201971220303994

https://www.thelancet.c Use of anakinra in patients who The Lancet Anakinra for severe forms of COVID‐19: a om/journals/lanrhe/artic 29‐May‐20 Cohort study France Huet et al. NA Anakinra were admitted to hospital for Rheumatology cohort study le/PIIS2665‐ severe forms of COVID‐19 9913(20)30164‐8/fulltext

Safety, tolerability, and immunogenicity of a https://www.thelancet.c Are different doses of Ad5 recombinant adenovirus type‐5 vectored om/journals/lancet/articl Ad5 vectored COVID‐19 22‐May‐20 The Lancet CT China Feng‐Cai Zhu et al. NCT04313127 vectored COVID‐19 vaccine safe COVID‐19 vaccine: a dose‐escalation, open‐ e/PIIS0140‐ vaccine and immunogenic? label, non‐randomised, first‐in‐human trial 6736(20)31208‐3/fulltext A comparative study on the time to achieve negative nucleic acid testing and hospital https://www.researchsq Antiviral effect of danopevir or Comparative Danopevir and 29‐May‐20 Preprint stays between Danoprevir and China Zhicheng Zhang et al. uare.com/article/rs‐ NA lopinavir/ritonavir in COVID‐19 study lopinavir/ritonavir Lopinavir/Ritonavir in the treatment of 28376/v1.pdf patients patients with COVID‐19 Potential of Arbidol for Post‐exposure https://link.springer.com Current Prophylaxis of COVID‐19 Transmission–A Observational Is Arbidol effective in profylaxis of 01‐Jun‐20 China Zhang et al. /content/pdf/10.1007/s1 NA Arbidol Medical Science Preliminary Report of a Retrospective Cohort study COVID? Study 1596‐020‐2203‐3.pdf Advanced Interferon beta‐1a as a Candidate for COVID‐ http://ajem.tums.ac.ir/in Journal of IRCT2015091402401 Is interferon beta1a effective in 26‐May‐20 19 Treatment; An Open‐label Single‐Arm CT Iran Payandemehr et al. dex.php/ajem/article/vie Interferon beta1a Emergency 7N1 treatment of COVID‐19? Clinical Trial Medicine w/454/307 Efficacy and safety of interferon beta‐1a in https://aac.asm.org/cont To evaluate efficacy and safety of Davoudi‐Monfared et IRCT2010022800344 13 July 2020 Antiviral Agents treatment of severe COVID‐19: A randomized RCT Iran ent/early/2020/07/08/A Interferon beta‐1a IFN β‐1a in patients with severe al. 9N28 clinical trial AC.01061‐20 COVID‐19. Clinical https://www.medrxiv.or To develop and clinically evaluate A serological assay to detect SARS‐CoV‐2 Evaluation of g/content/10.1101/2020 IRB protocol an at‐home finger‐prick dried 30/05/2020 medRxiv antibodies in at‐home collected fingerprick USA Karp et al. Antibody diagnostic test diagnostic .05.29.20116004v2.full.p #20180015 blood spot test to detect SARS‐ dried blood spots test df CoV‐2 antibodies Clinical https://www.medrxiv.or To assess the analytical and Performance evaluation of the point‐of‐care Evaluation of UK/USA/South g/content/10.1101/2020 Nucleic acid diagnostic clinical performance of the 27/05/2020 medRxiv SAMBA II SARS‐CoV‐2 Test for detection of Assennato et al. N/A diagnostic Africa .05.24.20100990v2.articl test SAMBA II 83 SARS‐CoV‐2 Test SARS‐CoV‐2 test e‐info using panels and clinical samples. Clinical https://www.medrxiv.or To develop and clincally evaluate EasyCOV : LAMP based rapid detection of Evaluation of g/content/10.1101/2020 saliva RT‐LAMP a new simple saliva SARS‐CoV‐2 30/05/2020 medRxiv France L’Helgouach et al. N/A SARS‐CoV‐2 in saliva diagnostic .05.30.20117291v1.full.p diagnostic test detection test based on RT‐LAMP test df technology Clinical https://www.medrxiv.or To evaluate the performance of Evaluation of performance of two SARS‐CoV‐ Evaluation of g/content/10.1101/2020 Antibody rapid two COVID 19 IgM/IgG Rapid 27/05/2020 medRxiv 2 Rapid whole‐blood finger‐stick IgM‐IgG France Prazuck et al. N/A diagnostic .05.27.20112888v1.full.p diagnostic test Diagnostic Tests compared to the Combined Antibody Tests test df gold standard, RT‐PCR. To show the potential efficacy and Mortality reduction in 46 severe Covid‐19 https://www.medrxiv.or safety of hyperimmune plasma patients treated with hyperimmune plasma. proof of g/content/10.1101/2020 29/05/2020 medRxiv Italy Perotti et al. NCT 04321421 convalescent plasma infusions, obtained from A proof of concept single arm multicenter concept study .05.26.20113373v1.full.p convalescent donors, in COVID‐19 interventional trial df patients with respiratory failure https://www.medrxiv.or To analyse the outcomes of COVID‐ Use of High Flow Nasal Therapy to Treat 19 patients with moderate‐to‐ Retrospective g/content/10.1101/2020 26/05/2020 medRxiv Moderate to Severe Hypoxemic Respiratory USA Patel et al. High Flow Nasal Therapy severe hypoxemic respiratory analysis .05.22.20109355v1.full.p Failure in COVID‐19 failure receiving High Flow Nasal df Therapy

Hydroxychloroquine or chloroquine with or https://www.thelancet.c without a with or without a macrolide for Observational USA/Switzerla om/journals/lancet/articl Are these treatment regimens 22‐May‐20 The Lancet Mehra et al. NA Hydroxychloroquine treatment of COVID‐19: a multinational study nd e/PIIS0140‐ associated with in‐hospital death? registry analysis 6736(20)31180‐6/fulltext

https://www.frontiersin. Is Interferon‐a2b efficient in Frontiers in 15 May 2020 Interferon‐a2b Treatment for COVID‐19 CT Canada, China Qiong Zhou, et al. org/articles/10.3389/fim NA Interferon‐a2b accelerating viral clearance and Immunology mu.2020.01061/full reducing inflammation markers?

https://www.medrxiv.or To examine the role of early Clinical Early Short Course Corticosteroids in Retrospective g/content/10.1101/2020 corticosteroid therapy in patients 19 May 2020 Infectious USA Fadel et al. NCT04374071 corticosteroids Hospitalized Patients with COVID‐19 study .05.04.20074609v1.full.p with moderate to severe COVID‐ Diseases df 19. https://www.medrxiv.or Is convalescent plasma an Convalescent plasma treatment of severe Preprint medRxiv CT USA Sean T. H. Liu, et al. g/content/10.1101/2020 NA Convalescent plasma effective treatment for severe COVID‐19: A matched control study .05.20.20102236v1 COVID19?

Use of renin–angiotensin–aldosterone https://www.thelancet.c Case renin–angiotensin–aldos system inhibitors and risk of COVID‐19 Francisco J de Abajo, om/journals/lancet/articl Does use of RAAS predispose 14 May 2020 Lancet population Spain EUPAS34437 terone system inhibitors, requiring admission to hospital: a case‐ et al. e/PIIS0140‐ patients to severe COVID19? study RAAS population study 6736(20)31030‐8/fulltext

To evaluate various methods of chest compressions in patients Resuscitation of the patient with with suspected/confirmed SARS‐ suspected/confirmed COVID‐19 when https://journals.viamedic Cardiology Randomized CoV‐2 infection conducted by Preprint wearing personal protective equipment: A Poland Marek Malysz, et al. a.pl/cardiology_journal/a NA PPE Journal crossover trial medical students wearing full randomized multicenter crossover simulation rticle/view/68336 personal protective equipment trial (PPE) for aerosol generating procedures (AGP). Stefano Bonovas, https://www.nejm.org/d Re‐analysis of cumulative Compassionate Use of Remdesivir in Covid‐ Letters to the Gerd Fätkenheuer, 15 May 2020 NEJM International oi/full/10.1056/NEJMc20 NA Remdesivir incidence of improvement, 19 (Grein et al. ‐ NEMJ) editor Christian Hoffman, patient classification Jiayuan Wu 15312

https://www.clinicalmicr To evaluate the performance of Clinical A multiple center clinical evaluation of an Diagnostic obiologyandinfection.co an ultra‐fast single‐tube nucleic Preprint Microbiology ultra‐fast single‐tube assay for SARS‐CoV‐2 clinical China Ji Wang, et al. m/action/showPdf?pii=S NA Diagnostic test acid isothermal amplification and Infection RNA evaluation 1198‐ detection assay for SARS‐CoV‐2 743X%2820%2930284‐6 RNA Are combined A combined oropharyngeal/nares swab is a Diagnostic https://www.sciencedire Oropharyngeal/nares oropharyngeal/nares swab is a Journal of Preprint suitable alternative to nasopharyngeal swabs assay Canada Jason J., et al. ct.com/science/article/pi NA and nasopharyngeal suitable alternative for Clinical Virology for the detection of SARS‐CoV‐2 comparison i/S1386653220301840 swabs nasopharyngeal swabs for COVID19 sample colleciton? Can an AI model rapidly identify https://www.nature.com SARS‐CoV‐2 infection based on Artificial intelligence–enabled rapid diagnosis Diagnostic initial chest CT scans and 19 May 2020 Nature Chinq Xueyan Mei, et al. /articles/s41591‐020‐ N/A AI diagnostic algorithm of patients with COVID‐19 assay associated clinical information of 0931‐3 COVID‐19 (+) patients in the early stage? To investigate the effects of https://www.medrxiv.or dipeptidyl peptidase‐4 Effects of a DPP‐4 inhibitor and RAS blockade dipeptidyl peptidase‐4 (DPP‐4i) retrospective g/content/10.1101/2020 (DPP‐4i), 23‐May Medrxiv on clinical outcomes of patients with South Korea Sang Youl Rhee et al. N/A and renin–angiotensin system analysis .05.20.20108555v1.full.p renin–angiotensin diabetes and COVID‐19 (RAS) blockade on the short‐term system (RAS) blockade df clinical outcomes of COVID‐19 https://www.medrxiv.or Do COVID‐19 patients admitted to the ICU To investigate the prevalence of prospective g/content/10.1101/2020 anti‐Pneumocystis 22‐May Medrxiv require anti‐Pneumocystis jirovecii France Alanio N/A Pneumocystis jirovecii in COVID‐ cohort study .05.18.20105296v1.full.p jirovecii prophylaxis prophylaxis? 19 patients admitted to the ICU df To develop and validate a novel Development and clinical application of a https://www.medrxiv.or RT‐LAMP assay capable of 23/05/2020 Medrxiv rapid and sensitive loop‐mediated isothermal Diagnostic China Hu et al. g/content/10.1101/2020 N/A RT‐LAMP Diagnostic test detecting SARS‐CoV‐2 RNA for amplification test for SARS‐CoV‐2 infection .05.20.20108530v2 potential use in centralized facilities and point‐of‐care settings https://www.medrxiv.or Efficacy of siltuximab for Use of siltuximab in patients with COVID‐19 retrospective g/content/10.1101/2020 22 May 2020 Medrxiv Italy, UK Gritti et al. NCT04322188 siltuximab treatment of severe patients with pneumonia requiring ventilatory support analysis .04.01.20048561v3.full.p COVID‐19 df https://www.medrxiv.or To test if intravenous almitrine Almitrine as a non ventilatory strategy to Case control g/content/10.1101/2020 can improve hypoxia in 22‐May Medrxiv improve intrapulmonary shunt in COVID‐19 France Losser et al. N/A Almitrine series .05.18.20105502v1.full.p mechanically ventilated COVID‐19 patients df patients.

https://www.medrxiv.or To examine the benefit‐risk profile Systematic of remdesivir in COVID‐19 Remdesivir in treatment of COVID‐19: A g/content/10.1101/2020 12‐May MedRxiv benefit‐risk UK Davies et al. N/A Remdesivir patients compared to standard systematic benefit‐risk assessment .05.07.20093898v1.full.p assessment of care, placebo or other df treatments. Application of https://www.medrxiv.or To test the hypothesis that deep learning Assisting Scalable Diagnosis Automatically via g/content/10.1101/2020 application of deep learning to 3D 15‐May MedRxiv to China Liu et al. N/A Chest CT CT Images in the Combat against COVID‐19 .05.11.20093732v1.full.p chest CT images could help retrospective identify COVID‐19 infections. analysis df https://www.medrxiv.or To explore the association of The effects of ARBs, ACEIs and statins on ACEi/ARB and/or statins with retrospective g/content/10.1101/2020 15‐May MedRxiv clinical outcomes of COVID‐19 infection Belgium De Spiegeleer et al. N/A ARBs, ACEi, Statins clinical manifestations in COVID‐ analysis .05.11.20096347v1.full.p among nursing home residents 19 infected older people residing df in nursing homes. https://www.medrxiv.or To analyse key safety metrics expanded following transfusion of Early Safety Indicators of COVID‐19 g/content/10.1101/2020 14‐May MedRxiv access USA Joyner et al. NCT04338360 Convalescent plasma convalescent plasma in patients Convalescent Plasma in 5,000 Patients .05.12.20099879v1.full.p program with severe or life‐threatening df COVID‐19 To report the clinical course, https://www.medrxiv.or safety, and outcomes after Nebulized in‐line endotracheal dornase alfa Nebulized in‐line nebulized in‐line endotracheal retrospective g/content/10.1101/2020 15‐May MedRxiv and albuterol administered to mechanically USA Weber et al. NCT04387786 endotracheal Dornase dornase alfa treatment for case study .05.13.20087734v1.full.p ventilated COVID‐19 patients: A case series Alfa intubated and mechanically df ventilated patients with COVID‐ 19. https://www.medrxiv.or To determine if transfusion of Treatment of COVID‐19 Patients with g/content/10.1101/2020 convalescent plasma is a safe 13‐May MedRxiv Case series USA Salazar et al. N/A Convalescent plasma Convalescent Plasma in Houston, Texas .05.08.20095471v1.full.p treatment option for those with df severe COVID‐19 disease. http://viruseradication.c om/journal‐ A review of the safety of favipiravir – a details/A_review_of_the Journal of Virus Systematic Victoria Pilkington, et 30 April 2020 potential treatment in the COVID‐19 UK _safety_of_favipiravir_% NA Favipiravir Safety of favipiravir Eradication review al. pandemic? E2%80%93_a_potential_ treatment_in_the_COVI D‐19_pandemic%5E/

To evaluate the safety and impact - Allogeneic cardiosphere derived cells https://link.springer.com of administration of allogeneic Basic Research (CAP-1002) in critically ill CDCs, formulated for intravenous 12 May 2020 Case series USA Siddharth Singh, et al. /article/10.1007/s00395‐ NA CAP‐1002 in Cardiology COVID-19 patients: compassionate-use case (IV) series 020‐0795‐1 infusion as CAP‐1002, in critically ill COVID‐19 patients.

Efficacy and safety of corticosteroids in Canadian COVID‐19 based on evidence for COVID‐19, https://www.cmaj.ca/co Assess efficacy and safety of Systematic Medical other coronavirus infections, influenza, International ntent/cmaj/early/2020/0 corticosteroids for COVID19, Preprint Review ; Zhikang Ye, et al. NA Corticosteroids Association community‐acquired pneumonia and acute Collaboration 5/14/cmaj.200645.full.p SARS, MERS, CAP, ARDS and Meta‐analysis Journal respiratory distress syndrome: a systematic df influenza review and meta‐analysis

Clinical and Pilot prospective open, single‐arm https://www.clinexprheu To assess the efficacy and safety 1 May 2020 Experimental multicentre study on off‐label use of CT Italy S. Sciascia, et al. matol.org/abstract.asp?a NA Tocilizumab of tocilizumab in severe COVID19 Rheumatology tocilizumab in patients with severe COVID‐19 =15723 patients

Efficacy of different facial BMJ Global Facial protection for healthcare workers Scoping Laura R Garcia Godoy, https://gh.bmj.com/cont 23 April 2020 USA NA Facial protection protection devices, especially in Health during pandemics: a scoping review Review et al. ent/5/5/e002553 light of N95 respirator shortages Compassionate remdesivir treatment of severe Covid‐19 pneumonia in intensive care Comparative efficacy of Pharmacologica https://pubmed.ncbi.nlm Preprint unit (ICU) and Non‐ICU patients: Clinical Case series Italy Spinello Antinori, et al. NA Remdesivir remdesivir in ICU and non‐ICU l Research .nih.gov/32407959/ outcome and differences in post treatment patients hospitalisation status To evaluate which type of full‐ Personal protective equipment for https://www.cochranelib body PPE and which method of preventing highly infectious diseases due to donning or do.ing PPE have the Cochrane Systematic International rary.com/cdsr/doi/10.10 15 April 2020 exposure to contaminated body fluids in Verbeek JH, et al. NA PPE least risk of contamination or Library Review Collaboration 02/14651858.CD011621. healthcare infection for HCW, and which staff pub4/full training methods increase compliance with PPE protocols.

https://www.cochranelib To assess whether convalescent Convalescent plasma or hyperimmune plasma or hyperimmune Cochrane Systematic rary.com/cdsr/doi/10.10 14 May 2020 immunoglobulin for people with COVID‐19: a Netherlands Valk SJ, et al. NA Convalescent Plasma immunoglobulin transfusion is Library Review 02/14651858.CD013600 rapid review eJective and safe in the treatment /full of people with COVID‐19.

Journal of https://www.jacionline.o Preliminary assessment of the Allergy and Safety and efficacy of early high‐dose IV Emanuele Pontali, et Preprint Case series Italy rg/article/S0091‐ NA Anakinra safety and efficacy of anakirna in Clinical anakinra in severe COVID‐19 lung disease al. severe/moderate COVID19 Immunology 6749(20)30634‐5/fulltext

Tocilizumab for Treatment of Severe COVID‐ What is the role of tocilizumab Observational https://pubmed.ncbi.nlm 09 May 2020 Microorganisms 19 Patients: Preliminary Results From Italy Colaneri et al. NA tocilizumab therapy in severe COVID‐19 study .nih.gov/32397399/ SMAtteo COvid19 REgistry (SMACORE) patients?

Hydroxychloroquine in Patients With Mainly https://www.bmj.com/c Is hydroxychloroquine effective 14 May 2020 BMJ Mild to Moderate Coronavirus Disease 2019: RCT China Tang et al. ontent/369/bmj.m1849.l ChiCTR2000029868 Hydroxychloroquine and safe in COVID‐19 patients? Open Label, Randomised Controlled Trial ong

Clinical efficacy of hydroxychloroquine in patients with covid‐19 pneumonia who Observational https://www.bmj.com/c 05 May 2020 BMJ France Mahévas et al. NA Hydroxychloroquine Is hydroxychloroquine effective? require oxygen: observational comparative study ontent/369/bmj.m1844 study using routine care data To assess and compare the Clinical https://www.medrxiv.or performance of 6 rapid tests and Detection of SARS‐CoV‐2 antibodies using Evaluation of g/content/10.1101/2020 3 ELISAs for the diagnosis of 08 May 2020 MedRxiv commercial assays and seroconversion France Tuaillon et al. NCT04347850 Antibody diagnostic test diagnostic .05.04.20090027v3.full.p COVID‐19, and to explore patterns in hospitalized patients test df seroconversions in subjects with confirmed COVID‐19 Clinical https://www.medrxiv.or ddPCR: a more sensitive and accurate tool To compare the dynamic range evaluation of g/content/10.1101/2020 08 May 2020 MedRxiv for SARS‐CoV‐2 detection in low viral load China Suo et al. PCR diagnostic test and the limit of detection (LoD) diagnostic .02.29.20029439v2.full.p specimens between ddPCR and RT‐PCR test df To evaluate the efficacy and Clinical Outcomes and Plasma https://www.medrxiv.or safety of adding baloxavir Concentrations of Baloxavir Marboxil and g/content/10.1101/2020 baloxavir marboxil, 05 May 2020 MedRxiv RCT China Yan Lou et al. ChiCTR2000029544 marboxil or favipiravir to the Favipiravir in COVID‐19 Patients: an .04.29.20085761v1.full.p favipiravir current standard antiviral Exploratory Randomized, Controlled Trial df treatment https://www.medrxiv.or To determine if excessive PGE2 Celebrex adjuvant therapy on COVID‐19: An g/content/10.1101/2020 may be a key in the pathology of 11 May 2020 MedRxiv Clinical trial China Wenxin Hong et al. ChiCTR2000031630 Celebrex (Celecoxib) experimental study .05.05.20077610v1.full.p COVID‐19 and whether COX‐2 is a df critical target for therapy. To take into account the possible retrospective https://www.medrxiv.or confounders when analyzing the analysis of COVID‐19 Related Mortality: Is the BCG g/content/10.1101/2020 difference in mortality rates 05 May 2020 MedRxiv International Mexico Paredes et al. N/A BCG Vaccine Truly Effective? .05.01.20087411v1.full.p between countries with and mortality without history of a universal BCG rates df vaccination program. To determine if zinc sulfate added Hydroxychloroquine and azithromycin plus https://www.medrxiv.or zinc sulfate (as add‐on retrospective to hydroxychloroquine and zinc vs hydroxychloroquine and azithromycin g/content/10.1101/2020 therapy to 08 May 2020 MedRxiv observational USA Carlucci et al. N/A azithromycin may improve alone: outcomes in hospitalized COVID‐19 .05.02.20080036v1.full.p hydroxychloroquine and study outcomes among hospitalized patients azithromycin) df patients. https://www.medrxiv.or To evaluate the effectiveness of Efficacy of face mask in preventing Systematic g/content/10.1101/2020 the use of masks to prevent 05 May 2020 MedRxiv respiratory virus transmission: a systematic review and China Liang et al. N/A facemask .04.03.20051649v3.full.p laboratory‐confirmed respiratory review and meta‐analysis meta‐analysis df virus transmission. Impact of corticosteroid therapy on https://www.nature.com Evaluate the safety and efficacy of outcomes of persons with SARS‐CoV‐2, SARS‐ Meta‐ corticosteroids on SARS‐CoV‐2, 5 May 2020 Nature China Huan Li, et al. /articles/s41375‐020‐ NA Corticosteroids CoV, or MERS‐CoV infection: a systematic analyisis SARS‐CoV, and MERS‐CoV review and meta‐analysis 0848‐3.pdf infections Journal of https://www.biorxiv.org/ Can an efficient in‐silico trial base Biomedical and In Silico Trial to test COVID‐19 candidate Giulia Russo, Preprint Italy Giulia Russo, et al. content/10.1101/2020.0 NA Vaccine be developed, and can it evaluate Health vaccines: a case study with UISS platform et al. vaccine candidates? Informatics 5.06.080630v1.full.pdf

Were non‐pharmaceutical Effect of non‐pharmaceutical interventions https://www.nature.com Mathematical Non‐pharmaceutical interventions effective in reducing Preprint Nature to contain COVID‐19 in China China, UK, US Shengjie Lai, et al. /articles/s41586‐020‐ NA Modeling interventions the number of cases and speed of 2293‐x_reference.pdf the epidemic in mainland China? Continuous hydroxychloroquine or colchicine https://www.ncbi.nlm.ni Protective role of colchicine or Autoimmunity therapy does not prevent infection with SARS‐Retrospective Omer Gendelman, et Colchicine, 29 April 2020 Israel h.gov/pmc/articles/PMC NA hydroxychloriquine for COVID19 Reviews CoV‐2: Insights from a large healthcare analysis al. hydroxychloroquine infection database analysis 7198406/ Tocilizumab for the treatment of severe https://www.sciencedire COVID‐19 pneumonia with Is tocilizumab effective for Autoimmunity Observational ct.com/science/article/a Preprint hyperinflammatory syndrome and acute Italy Paola Toniati, et al. NA Tocilizumab improving respiratory condition in Reviews study bs/pii/S15689972203013 respiratory failure: A single center study of severe COVID19? 100 patients in Brescia, Italy 00 https://www.pnas.org/c Effective treatment of severe COVID‐19 Retrospective ontent/pnas/early/2020/ Efficacy and safety of tocilizumab April 29 2020 PNAS China Xiaoling Xua, et al. Tocilizumab patients with tocilizumab analysis 04/27/2005615117.full.p in sever COVID19 df Triple combination of interferon beta‐1b, https://www.thelancet.c lopinavir–ritonavir, and ribavirin in the interferon beta‐1b, om/journals/lancet/articl The efficacy and safety of 08 May 2020 The Lancet treatment of patients admitted to hospital RCT Hong Kong Hung et al. NCT04276688 lopinavir–ritonavir, e/PIIS0140‐ combination with COVID‐19: an open‐label, randomised, ribavirin phase 2 trial 6736(20)31042‐4/fulltext

Interleukin‐1 blockade with high‐dose https://www.thelancet.c anakinra in patients with COVID‐19, acute The Lancet Observational om/journals/lanrhe/artic 07 May 2020 respiratory distress syndrome, and Italy Cavalli et al. NCT04318366 anakinra Efficacy of anakinra Rheumatology study le/PIIS2665‐ hyperinflammation: a retrospective cohort study 9913(20)30127‐2/fulltext https://www.sciencedire Outcomes associated with TCZ Journal of Supportive Treatment with Tocilizumab for Systematic ct.com/science/article/pi 19 April 2020 USA Alzghari et al. NA NA treatment in patients with COVID‐ Clinical Virology COVID‐19: A Systematic Review Review i/S1386653220301220?v 19 ia%3Dihub

Umifenovir treatment is not associated with https://www.clinicalmicr Effectiveness and safety of improved outcomes in patients with Retrospective obiologyandinfection.co 25 April 2020 Microbiology and China N. Lian, et al. NA Umifenovir (Arbidol) umifenovir for moderate COVID‐ coronavirus disease 2019: A retrospective CT m/article/S1198‐ 19 study 743X(20)30234‐2/fulltext

https://www.ncbi.nlm.ni Is Baricitinib an effective drug for Baricitinib therapy in COVID‐19: A pilot study clinical and respiratory 16 April 2020 ournal of Infectio CT Italy Fabrizio Cantini, et al. h.gov/pmc/articles/PMC NA Baricitinib on safety and clinical impact improvement in moderate 7177073/ COVID19 patients? https://www.medrxiv.or Mandated Bacillus Calmette‐Guérin (BCG) Does BCG vaccination serve as a growth curve g/content/10.1101/2020 04 May 2020 medRxiv vaccination predicts flattened curves for the USA Berg et al. N/A BCG vaccination protective factor against COVID‐ analysis .04.05.20054163v5.full.p spread of COVID‐19 19 df regression https://www.medrxiv.or Does TB Vaccination Reduce COVID‐19 analysis g/content/10.1101/2020 To assess the effectiveness of BCG 22 April 2020 medRxiv Infection? No Evidence from a Regression based on USA/ Japan Fukui et al. N/A BCG vaccination .04.13.20064287v1.full.p vaccination against COVID‐19 Discontinuity Analysis observational data df https://www.medrxiv.or A Novel Protein Drug, Novaferon, as the g/content/10.1101/2020 Novaferon, To determine the antiviral effects 29 April 2020 medRxiv RCT China Fang Zheng et al. ChiCTR2000029496 Potential Antiviral Drug for COVID‐19 .04.24.20077735v1.full.p Lopinavir/Ritonavir of Novaferon for COVID‐19 df To summarise the data on all Review and methodological analysis of trials https://www.medrxiv.or currently tested treatment and all treatment and currently testing treatment and prevention Systematic Greece, g/content/10.1101/2020 prevention options for COVID‐19, 01 May 2020 medRxiv Fragkou et al. N/A preparation options for options for the novel coronavirus disease review France .04.27.20080226v1.full.p and to methodologically analyse covid‐19 (COVID‐19) globally. df and evaluate the quality of the registered interventional studies https://www.medrxiv.or Could hydroxychloroquine Hydroxychloroquine application is associated retrospective g/content/10.1101/2020 administration be beneficial in the 01 May 2020 medRxiv with a decreased mortality in critically ill China Bo Yu et al. N/A Hydroxychloroquine analysis .04.27.20073379v1.full.p treatment of critically ill patients patients with COVID‐19 df with COVID‐19? https://www.medrxiv.or To determine if anti‐hypertensive Hypertension and Renin‐Angiotensin‐ retrospective g/content/10.1101/2020 drugs are harmful or beneficial to 29 April 2020 medRxiv Aldosterone System Inhibitors in Patients USA Ip et al. N/A anti‐hypertensive agents analysis .04.24.20077388v1.full.p Covid‐19 patients with with Covid‐19 df hypertension To evaluate the antiviral efficacy Lopinavir‐ritonavir alone or combined with https://www.medrxiv.or of lopinavir/ritonavir alone or arbidol in the treatment of 73 hospitalized retrospective g/content/10.1101/2020 lopinavir/ritonavir, 29 April 2020 medRxiv China Xiu Lan et al. N/A combined with arbidol in the patients with COVID‐19: a pilot retrospective analysis .04.25.20079079v1.full.p arbidol treatment of hospitalized patients study df with COVID‐19.

Preliminary evidence from a multicenter https://www.medrxiv.or prospective To assess the efficacy and safety prospective observational study of the safety g/content/10.1101/2020 04 May 2020 medRxiv observational China Mingxing Huang et al. (ChiCTR2000029609 Chloroquine of chloroquine with different and efficacy of chloroquine for the treatment .04.26.20081059v1.full.p study doses in COVID‐19 of COVID‐19 df https://www.medrxiv.or To evaluate the effects of QT Interval Prolongation and Torsade De Hydroxychloroquine/Azithromycin retrospective g/content/10.1101/2020 Hydroxychloroquine, 01 May 2020 medRxiv Pointes in Patients with COVID‐19 treated USA/Italy Chorin et al. N/A on the QT interval and the analysis .04.27.20074583v1.full.p Azithromycin with Hydroxychloroquine/Azithromycin arrhythmic risk in patients with df SARS‐CoV‐2 infection. https://www.medrxiv.or To assess and compare all nucleic Performance & Quality Evaluation of diagnostic kit David Surace Kapitula g/content/10.1101/2020 01 May 2020 medRxiv China N/A qPCR Diagnostic test acid‐based COVID‐19 testing kits Marketed COVID‐19 RNA Detection Kits evaluation et al. .04.25.20080002v1.full.p from quality control perspectives df To determine the relative risk of https://www.medrxiv.or azithromycin, drug‐induced Long QT Syndrome Risk of drug‐induced Long QT Syndrome chloroquine, favipiravir, (LQTS) associated with SARS‐CoV‐ Systematic g/content/10.1101/2020 29 April 2020 medRxiv associated with the use of repurposed COVID‐ USA/Canada Michaud et al. N/A hydroxychloroquine, 2 (COVID‐19) proposed review .04.21.20066761v2.full.p 19 drugs: a systematic review lopinavir/ritonavir, repurposed drugs compared to df remdesivir well‐known torsadogenic compounds retrospective analysis, Bayesian https://www.medrxiv.or To evaluate the risk of overdose Concentration‐dependent mortality of logostic Thailand/ UK/ g/content/10.1101/2020 for chloroquine treatment or 29 April 2020 medRxiv Watson et al. N/A Chloroquine chloroquine in overdose regression, France .04.24.20078303v1.full.p prevention regimens currently pharmacodyn df being trialled in COVID19 amic modelling https://www.thelancet.c Remdesivir in adults with severe COVID‐19: a om/journals/lancet/articl Effect of remdesivir in COVID‐19 29 April 2020 The Lancet randomised, double‐blind, placebo‐ RCT China Wang et al. NCT04257656 remdesivir e/PIIS0140‐ patients controlled, multicentre trial 6736(20)31022‐9/fulltext A Rapid Systematic Review of Clinical Trials Academic https://onlinelibrary.wile Utilizing Chloroquine and Systematic Analyze current literature to find 02 May 2020 Emergency USA Chowdhury et al. y.com/doi/abs/10.1111/ NA NA Hydroxychloroquine as a Treatment for review the role of CQ and HCQ Medicine COVID‐19. acem.14005 Clinical Efficacy of Intravenous https://www.medrxiv.or To determine the clinical efficacy intravenous Immunoglobulin Therapy in Critical Patients retrospective g/content/10.1101/2020 of intravenous immunoglobulin 20 April 2020 medRxiv China Ziyun Shao et al. N/A immunoglobulin (IVIG) with COVID‐19: A Multicenter Retrospective cohort study .04.11.20061739v2.full.p (IVIG) therapy in COVID‐19 therapy Cohort Study df patients. To establish best‐evidence to Chloroquine dosing recommendations for pharmacokin https://ascpt.onlinelibrar Clin Pharmacol inform pediatric Chloroquine 22 April 2020 pediatric COVID‐19 supported by modeling etic (PBPK) Netherlands Verscheijden et al. y.wiley.com/doi/10.1002 N/A Chloroquine Ther. doses for children infected with and simulation. model /cpt.1864 COVID‐19 Effect of High vs Low Doses of Chloroquine To evaluate the safety & efficacy Diphosphate as Adjunctive Therapy for https://jamanetwork.co JAMA Network of different dosages of 24 April 2020 Patients Hospitalized With Severe Acute RCT Brazil Borba et al m/journals/jamanetwork NCT04323527 Chloroquine Open chloroquine in patients with Respiratory Syndrome Coronavirus 2 (SARS‐ open/fullarticle/2765499 severe COVID‐19. CoV‐2) Infection: A Randomized Clinical Trial.

A Randomized, Single‐blind, Group https://www.medrxiv.or To evaluate the clinical efficacy sequential, Active‐controlled Study to g/content/10.1101/2020 and safety of α‐Lipoic acid (ALA) 21 April 2020 medRxiv evaluate the clinical efficacy and safety of α‐ RCT China Zhong et al. ChiCTR2000029851 α‐Lipoic acid (ALA) .04.15.20066266v1.full.p for critically ill patients with Lipoic acid for critically ill patients with COVID‐19. coronavirus disease 2019（COVID‐19） df

To systematically retrieve and Effectiveness and Safety of Glucocorticoids Rapid review https://www.medrxiv.or summarize the current evidence 22 April 2020 medRxiv to Treat COVID‐19: A Rapid Review and Meta‐ and meta‐ China Shuya Lu et al g/content/10.1101/2020 N/A Glucocorticoids of the effectiveness and safety of Analysis analysis .04.17.20064469v1 glucocorticoid therapy for patients with COVID‐19

https://www.medrxiv.or To assess the effectiveness of A systematic review of Anakinra, Systematic g/content/10.1101/2020 Anakinra, Tocilizumab, specific interleukin‐1 and ‐6 26 April 2020 MedRxiv Tocilizumab, Sarilumab and Siltuximab for UK Khan et al N/A review .04.23.20076612v1.full.p Sarilumab, Siltuximab inhibitors for the treatment of coronavirus‐related infections df coronavirus‐related infections. https://www.cytodyn.co Preliminary m/newsroom/press‐ Southern California Patients Treated with results from releases/detail/415/sout 13 April 2020 Press release Leronlimab for COVID‐19 under Emergency USA CytoDyn INC. NA leronlimab Could leronlimab be effective? clinical trial hern‐california‐patients‐ IND treated‐with‐leronlimab‐ for Transplantation of ACE2‐ Mesenchymal Stem Aging and http://dx.doi.org/10.143 ACE2‐mesenchymal Efficacy of MSC transplantation in 28 February 2020 Cells Improves the Outcome of Patients with CT China Leng et al. ChiCTR2000029990 Disease 36/AD.2020.0228 stem cell COVID patients COVID‐19 Pneumonia Journal of https://onlinelibrary.wile Tocilizumab treatment in COVID‐19: a single Observational What are treatment responses of 26 March 2020 Medical China Luo et al. y.com/doi/full/10.1002/j NA tocilizumab center experience study TCZ in the COVID‐19 patients? Virology mv.25801 Association of Inpatient Use of Angiotensin To determine the association Angiotensin‐converting Converting Enzyme Inhibitors and https://www.ahajournals between in‐hospital use of Circulation Observational enzyme inhibitors 17 April 2020 Angiotensin II Receptor Blockers with China Zhang et al. .org/doi/10.1161/CIRCRE NA ACEI/ARB and all‐cause mortality Research study (ACEIs) and Angiotensin Mortality Among Patients With Hypertension in COVID‐19 patients with SAHA.120.317134 receptor blockers (ARBs) Hospitalized With COVID‐19 hypertension

Association of Renin‐Angiotensin System Asses the association between Angiotensin‐converting Inhibitors With Severity or Risk of Death in https://jamanetwork.co ACEIs/ARBs and severity of illness enzyme inhibitors 23 April 2020 JAMA Patients With Hypertension Hospitalized for Case series China Juy Li, et al m/journals/jamacardiolo NA and mortality in patients with (ACEIs) and Angiotensin Coronavirus Disease 2019 (COVID‐19) hypertension hospitalized for gy/fullarticle/2765049 receptor blockers (ARBs) Infection inWuhan, China COVID‐19 infection.

Acta https://www.sciencedire Is treatment with dipyridamol Potential therapeutic effects of dipyridamole PrePrint Pharmaceutica RCT China Xiaoyan Liu, et al. ct.com/science/article/pi NA Dipyridamole clinically effetive in severly ill in the severely ill patients with COVID‐19 Sinica B i/S2211383520305529 COVID19 patients?

Benefits and Risks of Chloroquine and https://www.medrxiv.or To evaluate the efficacy and Hydroxychloroquine in The Treatment of meta‐analysis g/content/10.1101/2020 chloroquine/hydroxycho 18 April 2020 medRxiv China/ USA Jing Wang et al safety of Chloroquine and Viral Diseases: A Meta‐Analysis of Placebo of RCTs .04.13.20064295v1.full.p roquine hydroxychloroquine Randomized Controlled Trials df To assess the effectiveness of Physical interventions to interrupt or reduce https://www.medrxiv.or hand hygiene, surface systematic Saudi Arabia, the spread of respiratory viruses. Part 2 ‐ g/content/10.1101/2020 disinfecting, and other hygiene 20 April 2020 medRxiv review and Australia, Al‐Ansary NA hygiene interventions Hand hygiene and other hygiene measures: .04.14.20065250v1.full.p interventions in preventing or meta‐analysis Canada systematic review and meta‐analysis. df reducing the spread of illnesses from respiratory viruses

To investigate the efficacy and An experimental trial of recombinant human https://www.medrxiv.or Recombinant human safety of recombinant human interferon alpha nasal drops to prevent g/content/10.1101/2020 17 April 2020 medRxiv Clinical trial China Meng et al. NCT04320238 interferon‐alpha nasal interferon alpha1b (rhIFN‐α) nasal coronavirus disease 2019 in medical staff in .04.11.20061473v1.full.p drops drops in healthy medical staff to an epidemic area df prevent COVID‐19. An exploratory randomized, controlled study on the efficacy and safety of https://www.medrxiv.or 23 March 2020, Lopinavir‐Ritonavir combination lopinavir/ritonavir or arbidol treating adult g/content/10.1101/2020 lopinavir/ritonavir updated 15 April medRxiv RCT China Li et al. NCT04252885 compared to Arbidol compared to patients hospitalized with mild/moderate .03.19.20038984v2.full.p (Kaletra), arbidol 2020 no antiviral treatment COVID‐19 (ELACOI) df

https://www.medrxiv.or To assess the potential Potential Effectiveness and Safety of Antiviral review and g/content/10.1101/2020 effectiveness and safety of 17 April 2020 medRxiv Agents in Children with Coronavirus Disease China Shi et al. NA antivirals meta‐analysis .04.13.20064436v1.full.p antiviral agents for COVID‐19 in 2019: A Rapid Review and Meta‐Analysis df children. https://www.medrxiv.or The aim of this review was to Efficacy and Safety of Antibiotic Agents in g/content/10.1101/2020 evaluate the efficacy and safety of 17 April 2020 medRxiv rapid review China Wang et al NA antibiotics Children with COVID‐19: A Rapid Review .04.13.20064402v1.full.p antibiotic agents in children with df COVID‐19 No evidence of rapid antiviral clearance or https://www.sciencedire Is hydroxychloroquine effecitve Médécine et Prospective clinical ben‐efit with the combination of ct.com/science/article/pi Hydroxychloroquine, for viral clearance when Preprint Maladies virological France JM Molina et al. NA hydroxychloroquine and azithromycin in i/S0399077X20300858?v azithromycin reproducing the study of Gautrel Infectieuses assay patients with severe COVID‐19 infection ia%3Dihub et al.?

Grant from the National Natural https://www.sciencedire Science Foundation The effect of corticosteroid treatment on of China (Jing Liu, Evaluate the influence of Accepted 31 Journal of ct.com/science/article/pi patients with coronavirus infection: a Meta‐analysis China Zhenwei Yang, et al. grant no. 81472735 Corticosteroids corticosteroids in patients with March 2020 Infection i/S0163445320301912?v systematic review and meta‐analysis ) and the Wuhan coronavirus. ia%3Dihub University (Jing Liu, grant no. 2042019kf0206 Clinical Towards Optimization of https://academic.oup.co What is the best dose of Prospective Preprint Infectious Hydroxychloroquine Dosing in Intensive Care France Sophie Perinel et al, m/cid/article/doi/10.109 NA Hydroxychloroquine hydroxychloroquine for COVID19 PK study Diseases Unit COVID‐19 Patients 3/cid/ciaa394/5816960 patients? https://academic.oup.co Journal of Is cholorquine better than m/jmcb/article/doi/10.1 Chloroquine, lopinavir, Molecular Cell Treating COVID‐19 with Chloroquine RCT China Mingxing Huang, et al. NA lopinavir/ritonavir in severe and 093/jmcb/mjaa014/5814 ritonavir Biology moderate COVID19 patients? 655 https://www.nejm.org/d Compassionate Use of Remdesivir for UK, Canada, 10 April 2020 NEJM Report Grein et al. oi/full/10.1056/NEJMoa2 NA Remdesivir NA Patients with Severe Covid‐19 Europe, Japan 007016 https://www.sciencedire A systematic review on the efficacy and Summary of the existing the Journal of Systematic Andrea Cortegiani, et ct.com/science/article/pi 10 March 2020 safety of chloroquine for the treatment of Italy NA Chloroquine evidence on chloroquine for the Critical Care review al. i/S0883944120303907?v COVID‐19 treatment of COVID‐19 ia%3Dihub Systematic review of the clinical Journal Systematic review of the efficacy and safety https://onlinelibrary.wile outcomes of using antiretroviral Systematic Preprint International of antiretroviral drugs against SARS, MERS, or Switzerland N Ford et al. y.com/doi/10.1002/jia2. NA Antiretroviral drugs drugs for the prevention and review AIDS Society COVID‐19: initial assessment 25489 treatment of coronaviruses and planned clinical trials

Ethics committees Investigate the effects of 6‐week of Hainan General respiratory rehabilitation training Complementary Respiratory rehabilitation in elderly patients Non‐ https://www.sciencedire Hospital and Respiratory on respiratory function, QoL, 30 March 2020 Therapies in with COVID‐19: A randomized controlled interventional China Kai Liu, et al. ct.com/science/article/pi Huanggang Central rehabilitation training mobility and psychological Clinical Practice study RCT Hospital (approval i/S1744388120304278 function in elderly patients with numbers: 19758 and COVID‐19 20200125) Investigate the effect of Complementary Effects of progressive muscle relaxation on Non‐ https://www.sciencedire Progressive muscle progressive muscle relaxation on 6 March 2020 Therapies in anxiety and sleep quality in patients with interventional China Kai Liu, et al. ct.com/science/article/pi NA relaxation (sleep anxiety and sleep quality of COVID‐ Clinical Practice COVID‐19 RCT therapy) i/S1744388120302784 19 patients First Clinical Study Using HCV Protease https://www.medrxiv.or Inhibitor Danoprevir to Treat Naïve and g/content/10.1101/2020 Effect of danoprevir in moderate 24 March 2020 MedRxiv CT China Chen et al. NCT04291729 danopevir/ritonavir Experienced .03.22.20034041v1.full.p COVID‐19 patients COVID‐19 Patients df The potential of low molecular weight https://www.medrxiv.or heparin to mitigate cytokine storm in severe Retrospective 07 April 2020 MedRxiv China Chen Shi et al. g/content/10.1101/2020 not found enoxaparin Efficacy of enoxaparin covid‐19 patients: a retrospective clinical CT study .03.28.20046144v2 No evidence of clinical efficacy of https://www.medrxiv.or hydroxychloroquine in patients hospitalised To assess the effectiveness of Retrospective Matthieu Mahévas et g/content/10.1101/2020 14 April 2020 MedRxiv for COVID‐19 infection and requiring oxygen: France NA Hydroxychloroquine Hydroxychloroquine in patients analysis al. .04.10.20060699v1.full.p results of a study using routinely collected with severe Covid‐19 data to emulate a target trial df Grants: National Science and Technology Major Project (2018ZX10711001, 2017ZX10103011, 2017ZX10204401), Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005), China Postdoctoral Science Foundation https://jamanetwork.co (2019T120147, Is plasma from convalescente Treatment of 5 critically ill patients with Observational 27 March 2020 JAMA China C Shen, et al. m/journals/jama/fullartic 2018M641508), Convalescent plasma patients beneficial for critically ill COVID‐19 with convalescent plasma study le/2763983 Shenzhen Science COVID19 patients? and Technology Research and Development Project (202002073000001) , National Natural Science Foundation of China (81902058), Shenzhen Science and Technology Research and Development Project Proceedings of the National The feasibility of convalescent plasma Observational https://www.pnas.org/c Is treatment with convalescent Academy of 6 April 2020 therapy in severe COVID‐19 patients: a pilot /retrospectiv China Kai Duan et al ontent/early/2020/04/0 ChiCTR2000030048 Convalescent plasma plasma safe and beneficial for Sciences of the study e control COVID19 patients? United States of 2/2004168117 America

Compare medical masks to N95 Influenza and Medical Masks vs N95 Respirators for https://onlinelibrary.wile respirators in preventing other Preventing COVID‐19 in Health Care Workers Systematic Jessica J Bartoszko, et N95 respirators vs laboratory confirmed viral Preprint Canada y.com/doi/pdf/10.1111/i NA Respiratory ‐ A Systematic Review and Meta‐Analysis of review al. surgical masks infection and respiratory illness Viruses Randomized Trials rv.12745 including coronavirus specifically in health care workers.

https://www.cambridge. org/core/journals/disast er‐medicine‐and‐public‐ health‐ preparedness/article/ran Is attending one live training RANDOMIZED TRIAL OF INSTRUCTOR‐LED domized‐trial‐of‐ Disaster session or watching video TRAINING VERSUS VIDEO LESSON IN instructorled‐training‐ Medicine and Training on personal trainings over a month more Preprint TRAINING HEALTH CARE PROVIDERS IN RCT Denmark L Christensen et al versus‐video‐lesson‐in‐ NA Public Health protective equipment effective for training on downing PROPER DONNING AND DOFFING OF Preparedness training‐health‐care‐ and doffing personal protective PERSONAL PROTECTIVE EQUIPMENT providers‐in‐proper‐ equipment? donning‐and‐doffing‐of‐ personal‐protective‐ equipment/CF08F4727D A9D536883ECBFD04BC2 570 Performance of VivaDiagTM COVID‐19 Journal of https://onlinelibrary.wile To assess an easy to perform IgM/IgG Rapid Test is inadequate for Diagnostic Diagnostic serological Preprint Medical Italy Irene Cassantini et al. y.com/doi/epdf/10.1002 NA serological assay for diagnosis of diagnosis of COVID‐19 in acute patients assay assay Virology COVID19 referring to emergency room department /jmv.25800 DOI: 10.1128/JCM.0 0461‐20; Hospital Ethics Committee of Evaluation of Nucleocapsid and Spike Protein‐ https://jcm.asm.org/cont Joural of Clinical Diagnostic the General Hospital Diagnostic serological Evaluate the diagnostic feasibility Preprint based ELISAs for detecting antibodies against China Wanbing Liu, et al. ent/early/2020/03/27/JC Microbiology assay of the Central assay of two ELISA assays SARS‐CoV‐2 M.00461‐20 Theater Command 107 of the PLA ([2020]003‐1)

Article originally Australian New published in A cluster randomised trial of cloth masks Zealand Clinical To compare the efficacy of cloth Australia https://bmjopen.bmj.co medical masks, cloth 2015; authors BMJ Open compared with medical masks in healthcare RCT MacIntyre CR et al. Trials Registry: masks to medical masks in /Vietnam m/content/5/4/e006577 masks added comment workers ACTRN12610000887 hospital healthcare workers on 30/03/2020 077. Efficacy of hydroxychloroquine in patients https://www.medrxiv.or Assess the efficacy of 31 March 2020 MedRxiv with COVID‐19: results of a randomized RCT China Zhaowei Chen et al. g/content/10.1101/2020 ChiCTR2000029559 Hydroxychloroquine hydroxychloroquine clinical trial .03.22.20040758v2

Clinical and microbiological effect of a https://www.mediterran combination of hydroxychloroquine and Assess the efficacy of ee‐infection.com/wp‐ Hydroxychloroquine, Preprint azithromycin in 80 COVID‐19 patients with at RCT France Gautret et al. NA hydroxychloroquine associated content/uploads/2020/0 Azithromycin least a six‐day follow up: an observational with azithromycin study 3/COVID‐IHU‐2‐1.pdf

An exploratory randomized, controlled study on the efficacy and safety of 23 March 2020 https://www.medrxiv.or Lopinavir‐Ritonavir combination lopinavir/ritonavir or arbidol treating adult lopinavir/ritonavir (preprint, not yet BMJ RCT China Li et al. g/content/10.1101/2020 NCT04252885 compared to Arbidol compared to patients hospitalized with mild/moderate (Kaletra), arbidol peer‐reviewed) no antiviral treatment COVID‐19 (ELACOI) .03.19.20038984v1

ChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837, Breakthrough: Chloroquine phosphate has https://www.jstage.jst.g ChiCTR2000029826, shown apparent efficacy in treatment of Summary of ChiCTR2000029803, 10 Feb 2020 Biosci Trends China Gao et al. o.jp/article/bst/14/1/14_ Chloroquine Could chloroquine be effective? COVID‐19 associated pneumonia in clinical 15 CTs ChiCTR2000029762, studies. 2020.01047/_article ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, and ChiCTR2000029542

https://www.cytodyn.co Three Additional Patients with Severe COVID‐ Preliminary m/newsroom/press‐ not published 19 Treated with Leronlimab in New York results from releases/detail/401/thre 30 March 2020 USA CytoDyn Inc. NA Leronlimab Could leronlimab be effective? yet Medical Center Bringing the Total to 10 clinical trial e‐additional‐patients‐ Patients with‐severe‐covid‐19‐ treated‐with https://www.medrxiv.or Favipiravir versus Arbidol for COVID‐19: A Conventional therapy + favipiravir 27 March 2020 medRxiv RCT China Chang Chen et al. g/content/10.1101/2020 ChiCTR2000030254 Favipiravir, Arbidol Randomized Clinical Trial or arbidol? .03.17.20037432v2 International Hydroxychloroquine and azithromycin as a https://www.sciencedire Journal of EudraCT number Hydroxychloroquine, Role of hydroxychloroquine on 20 March 2020 treatment of COVID‐19: results of an open‐ CT France Gautret et al. ct.com/science/article/pi Antimicrobial 2020‐000890‐25 Azithromycin respiratory viral loads label non‐randomized clinical trial Agents i/S0924857920300996#! https://www.ncbi.nlm.ni Lopinavir‐Ritonavir combination A Trial of Lopinavir‐Ritonavir in Adults lopinavir/ritonavir 19 March 2020 N Engl J Med RCT China Cao et al. h.gov/pubmed/3218746 ChiCTR2000029308 compared to conventional Hospitalized with Severe Covid‐19. (Kaletra) 4 therapy ? https://www.sciencedire Arbidol combined with LPV/r versus LPV/r Arbidol and lopinavir‐ritonavir Journal of Retrospective ct.com/science/article/pi Lopinavir/ritonavir, 11 March 2020 alone against Corona Virus Disease 2019: A China Lisi Deng NA compared to lopinavir‐ritonavir Infection cohort study i/S0163445320301134?v Arbidol retrospective cohort study only? ia%3Dihub What is the efficacy and safety of High‐flow nasal‐oxygenation‐ assisted https://bjanaesthesia.org high‐flow nasal oxygenation British Journal fibreoptic tracheal intubation in critically ill High‐flow nasal In press RCT China Cai‐Neng Wu et al. /article/S0007‐ ChiCTR2000029658 during fibreoptic bronchoscopic of Anaesthesia patients with COVID‐19 pneumonia: a oxygnation intubation in critically ill patients prospective randomised controlled trial 0912(20)30135‐5/fulltext with COVID‐19?

Chinese Journal Efficacy of lopinavir, ritonavir and Arbidol for 2020 Pre‐print Retrospective http://rs.yiigle.com/yufa Lopinavir/ritonavir, Efficacy of lopinavir/ritonavir and of Infectious the treatment of new coronavirus China Chen Jun et al. NA online analysis biao/1182592.htm Arbidol arbidol Diseases, pneumonia Journal of Zhejiang http://www.zjujournals.c University A pilot study of hydroxychloroquine in om/med/CN/10.3785/j.is Role of hydroxychloroquine on 2020 (Medical treatment of patients with common RCT China Chen Jun et al. NCT04261517 Hydroxychloroquine sn.1008‐ respiratory viral loads Science) 2020 , coronavirus disease‐19 (COVID‐19) Vol. 49 Issue 9292.2020.03.03 (1) Assess the efficacy and safety of Meplazumab treats COVID‐19 pneumonia: an meplazumab, a humanized anti‐ https://doi.org/10.1101/ 2020 Pre‐print MedRxiv open‐labelled, concurrent controlled add‐on CT China Huijie Bian et al. NCT 04275245 Meplazumab CD147 antibody, as add‐on 2020.03.21.20040691 clinical trial therapy in patients with COVID‐19 pneumonia.

Total